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 ABSTRACT 
Adverse drug reactions (ADRs) are a major problem for drug companies and healthcare 
providers alike. Although ADRs can present anywhere in the body, the liver frequently 
effected, due to the relatively large concentrations of drugs it encounters. Drug induced liver 
injury (DILI) can occur through several different mechanisms. Bioactivation of drugs to 
reactive metabolites is believed to be a crucial step in the development of many cases of 
DILI. Nefazodone, an anti-depressant which was withdrawn due to hepatotoxicity, has been 
shown to be bioactivated to a reactive quinone-imine. The role of the mitochondria and their 
involvement in DILI is being increasingly recognised. The biguanides are known 
mitochondrial toxins, and phenformin and buformin were removed from the market due to 
unacceptably high incidents of lactic acidosis. The aims of this thesis were two-fold; to 
assess the bioactivation and irreversible binding of nefazodone and it safer analogue 
buspirone and to use the biguanides to assess mitochondrial toxicity in primary hepatocytes. 
In liver microsomes, both nefazodone and buspirone demonstrated NADPH-dependent 
irreversible binding, however, nefazodone irreversible binding was 9-fold that of buspirone. 
The metabolism of both nefazodone and buspirone was extensive and consisted mainly of 
hydroxylation and N-dealkylation reactions. In rat and human liver microsomes 
supplemented with GSH, nefazodone formed GSH conjugates with m/z 791 and m/z 807. 
This implied that the conjugates were formed from bioactivation of para-hydroxy 
nefazodone and dihydroxy-nefazodone. In rat liver microsomes, buspirone did not form any 
GSH conjugates. 
Further investigations of nefazodone and buspirone were carried out in freshly isolated rat 
hepatocytes. Metabolism of nefazodone and buspirone was investigated and revealed 
extensive metabolism of both compounds; however, GSH conjugates of neither compound 
were discovered. At 6 hours, both nefazodone and buspirone demonstrated significant 
irreversible binding (117.54±15.32 pmol equiv./mg protein and 84.43±30.93 pmol equiv./mg 
protein respectively) but only nefazodone demonstrated a significant decrease in cell 
viability (19.25±18.26 % control viability).  Inhibition studies, using ABT, significantly 
reduced the irreversible binding of nefazodone (49.34±4.64 pmol equiv./mg protein) but did 
not decrease cytotoxicity. This indicated that in rat hepatocytes the parent compound may be 
responsible for toxicity. 
Mitochondrial toxicity was investigated using the model mitochondrial toxins the 
biguanides. Initially, studies in cultured primary rat hepatocytes demonstrated that 
phenformin was the most potent mitochondrial toxin and dissipated the mitochondrial 
membrane potential, as measured by TMRM, within 24 hours (1.028±0.39% control 
fluorescence). This was taken forward to investigate mitochondrial toxicity in primary rat 
hepatocytes. Investigations into phenformin in rat hepatocytes demonstrated a high turnover 
to glucuronide metabolites and the novel metabolites [O, OMe] phenformin glucuronide and 
[2O] phenformin glucuronide were identified. Inhibition studies of CYP450 2D were 
undertaken using quinine (100µM) and this demonstrated significant inhibition of 
phenformin up to 200µM (AUC 47.30±47.30 without quinine vs AUC 648.80±121.28 with 
quinine). Despite increased phenformin concentrations, inhibition of phenformin metabolism 
ix 
 
did not produce overt cytotoxicity, however, lactate concentrations correlated with increased 
phenformin concentration. 
The work presented here highlights the need for a greater understanding of the role of 
bioactivation and irreversible binding in hepatotoxicity. It also demonstrates that whilst 
irreversible binding can help inform decisions as to whether a compound progresses into 
clinical trials, it should be made in the context of other safety assessments. Investigations 
into phenformin mitochondrial toxicity, illustrates the need to assess drugs and systems 
fully, to establish model compounds to investigate mechanisms of ADRs. A greater 
understanding of in vitro systems and the tools utilised to assess them, will benefit drug 
discovery and development. Ultimately, understanding these in vitro tests and the model 
compounds used to assess them, will help bridge the gap to man. 
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General introduction 
INTRODUCTION 
Adverse drug reactions (ADRs) are of great concern to the pharmaceutical industry 
and place a burden on medical services. Most ADRs are predictable, resulting from 
extension of the primary pharmacology of the drug, and come to light during pre-
clinical safety assessments and clinical trials. They often result from drug-drug 
interactions or a prescribing error (Olson et al. 2000). Idiosyncratic or unpredictable 
ADRs rarely come to light during clinical trials and are only detected once the drug 
has reached the wider market.  
Idiosyncratic reactions are generally considered to have different initiating factors, 
one of which is linked to the formation of reactive metabolites, which bind to 
proteins leading to toxicity. Many drugs that cause idiosyncratic reactions are now 
linked to reactive metabolite formation (Park et al. 2005). Detoxification of many 
reactive metabolites occurs via GSH conjugation (DeLeve, Kaplowitz 1991), and 
depletion of GSH is often required for toxicity to transpire. The irreversible binding 
of radiolabelled compounds or the identification of a GSH adduct of a drug in pre-
clinical testing, is now seen as a hazard signal for the potential of a drug to undergo 
bioactivation and therefore cause toxicity (Park et al. 2011). Of the drugs that are 
bioactivated, many contain ‘structural alerts’, chemical moieties that are often 
associated with bioactivation and resultant toxicity (Kalgutkar et al. 2005a). As such 
one approach to designing safer drugs is to avoid the use of structural alerts in drug 
design (Kalgutkar, Soglia 2005, Edwards, Sturino 2011). This is not always possible 
however, as the structural alert may be a vital part of the pharmacology of the drug. 
The use of structural alerts is further complicated by the fact that not all drugs with 
structural alerts are bioactivated and not all drugs that are bioactivated are toxic 
(Kalgutkar, Didiuk 2009). 
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Drugs that contain moieties associated with the formation of electrophilic quinones, 
quinone-imines and quinone-methides, such as phenols, hydroquinones, o-
aminophenols, p-aminophenols, alkylphenols and 5-oxo-indoles, are well established 
structural alerts (Edwards, Sturino 2011, Edwards, Sturino 2011). Quinone-imine 
formation has been well characterised through the model hepatotoxin, paracetamol. 
n-acetyl-p-benzoquinone-imine (NAPQI), the quinone-imine metabolic product of 
paracetamol has been shown to irreversibly bind to cellular proteins causing cell 
death through a variety of mechanisms (Bulera et al. 1995, Corcoran, Chung & 
Salazar 1987, Dietze et al. 1997a, Landin, Cohen & Khairallah 1996, Matthews et al. 
1997, Parmar et al. 1995, Tirmenstein, Nelson 1989). Nefazodone, an anti-depressant 
withdrawn in 2004, has been demonstrated to form quinone-imine reactive 
metabolites following hydroxylation para to nitrogen on the chlorophenylpiperazine 
ring system. It is thought that this metabolism is responsible for the idiosyncratic 
hepatotoxicity observed in man (Kalgutkar et al. 2005b, Bauman et al. 2008a). In 
contrast, buspirone, an anxiolytic agent, has the potential to be bioactivated on its 
pyrimidinylpiperazine moiety and yet appears not to be (Kalgutkar et al. 2005b), and 
there have been no reports of buspirone induced hepatotoxicity. There are also 
reports that the parent nefazodone structure is the toxic entity eliciting mitochondrial 
toxicity or BSEP inhibition (Dykens et al. 2008, Kostrubsky et al. 2006). 
Investigating the link between nefazodone toxicity and bioactivation, alongside the 
non-hepatotoxin buspirone, will help to further elucidate the structure-toxicity 
relationship of nefazodone. 
Although several drugs that cause idiosyncratic toxicity are thought to be due to 
reactive metabolite formation, metabolism is normally a detoxification process and 
the parent compound can also be involved in idiosyncratic toxicity. The biguanides 
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are anti-diabetic drugs, of which two, phenformin and buformin, have been 
withdrawn due to unacceptably high levels of lactic acidosis (Brown et al. 1998). It 
has been demonstrated that phenformin accumulates in mitochondria at 
concentrations up to 100-fold that in the cytosol (Davidoff 1971). It is not clear 
however why some patients developed lactic acidosis. Phenformin is metabolised by 
CYP450 2D6, a highly polymorphic enzyme, and it is a possibility that CYP450 2D6 
poor metabolisers are at increased risk of phenformin toxicity (Idle et al. 1981, Shah, 
Evans & Oates 1985, Shah et al. 1980). As an AMPK-activator, phenformin has 
been recommended for clinical trials in triple-negative and ER-positive breast cancer 
(Caraci et al. 2003, Appleyard et al. 2012) and identification of patients that are 
liable to develop lactic acidosis could aid a re-introduction into the clinic. 
The work presented in this thesis uses nefazodone, buspirone and phenformin to 
investigate the roles of reactive metabolite formation and parent compounds in drug 
induced toxicity, and the systems and biomarkers used to detect such toxicity.  
1.2 ADVERSE DRUG REACTIONS 
Adverse drug reactions (ADRs) are of great concern to the pharmaceutical industry 
and the medical profession. In the pharmaceutical industry 50% of drug candidates 
that enter pre-clinical trial studies fail to make it to clinical trial. Of those that 
advance to clinical testing, a further 30% are terminated due to unforeseen adverse 
effects (Kramer, Sagartz & Morris 2007). Of the drugs that do make it to market, in 
the 25 year period from 1975-2000 over 10% (56 of 548) of newly approved drugs 
were given a black box warning and a further 2.9% (16 of 548) had to be withdrawn 
from the market (Lasser et al. 2002). In the UK approximately 6.5% of hospital 
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admissions are as a result of an ADR (Pirmohamed et al. 2004) and as such are a 
financial burden to the NHS.  
ADRs can broadly be split into two categories, on-target and off-target reactions. 
On-target reactions are predictable and result from an extension of the known 
primary or secondary pharmacology of the drug (eg bleeding in a warfarin patient). 
These reactions show a clear dose-dependent relationship and can be avoided by 
lowering the dose. These reactions are rarely life threatening, and account for 80% of 
all drug reactions (Williams 2006). Off-target (idiosyncratic) reactions are not 
related to the primary or secondary pharmacology of the drug and show a complex 
dose relationship. Idiosyncratic reactions normally occur at therapeutic doses after an 
initial delay or latency period, which may range from a few days to several months. 
They occur at a frequency of 1 in 100 to 1 in 100,000 patients and are often related 
to the host-dependent factors such as genetic disposition and metabolism. It is 
unclear why so many idiosyncratic reactions occur, but they have been associated 
with the formation of reactive metabolites which may result in cell death or immune 
mediated reactions. 
1.3 DRUG INDUCED LIVER INJURY 
Drug induced liver injury (DILI) is the most frequent reason for black box warnings 
or withdrawal from the market and although only 10-20% of cases of DILI are 
deemed to be idiosyncratic; 75% of idiosyncratic reactions result in liver 
transplantation or death (Ostapowicz et al. 2002). DILI has become a major problem 
for clinicians, the pharmaceutical industry and regulatory agencies worldwide, not 
least because it is poorly predictable from pre-clinical animal studies. Acute liver 
failure is also not normally present in clinical trial phases of the drug due to the large 
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numbers of patients that would be required to participate for such an incidence to 
occur, therefore, DILI is normally not indicated as a problem until the post-
marketing stage. Between 1975 and 1999, 548 new drugs were approved by the 
FDA, of which 10 received a black box warning for hepatotoxicity and a further four 
were withdrawn (Lasser et al. 2002).   
In the clinic, DILI can either occur as an allergic or non-allergic reaction and may 
resemble other forms of liver disease including hepatitis and cholestasis. Allergic 
reactions are characterised by the presence of fever, rash, eosinophilia, a relatively 
short latency period (1-6 weeks) and rapid reoccurrence of the reaction (although this 
is normally deemed unethical). Autoantibodies directed towards the drug or a 
metabolite may also be present. Allergic DILI may also be accompanied by other 
severe reactions such as Steven Johnson syndrome. Non-allergic DILI is 
characterised by consistent absence of the above features of allergic reactions,  
tending to have a much longer latency period (1 month – 1 year) and unlike allergic 
reactions, may not produce a consistent reaction upon re-challenge.  
1.4 METABOLISM, REACTIVE METABOLITE FORMATION, COVALENT 
BINDING AND DILI 
Drug metabolism generally makes a drug less reactive and assists excretion of the 
drug from the body through increasing its lipophilicity. Occasionally metabolism 
causes bioactivation of a drug into a reactive metabolite. Reactive metabolites are 
normally deactivated by conjugation to GSH, however, if cell defences are impaired 
or overwhelmed these reactive metabolites are free to bind to cellular 
macromolecules and cause toxicity through a number of mechanisms (figure 1.1). 
This is particularly evident in the liver, which is the main site of metabolism. All 
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drugs administered orally pass through the liver via the portal vein before reaching 
the systemic circulation, therefore, the liver is often the site of ADRs. Post 1950, 13 
out of 21 (62%) of drugs withdrawn from the market or given a black box warning 
due to hepatotoxicity have been shown to produce reactive metabolites (Walgren, 
Mitchell & Thompson 2005) which have been implicated as a major cause of DILI. 
 
Figure 1.1. Schematic of metabolism and reactive metabolite formation. Following phase I metabolism, some molecules can be bioactivated to reactive metabolites. If these are not detoxified they can bind to macromolecules resulting in cell death, hypersensitivity reactions or carcinogenicity. 
1.4.1 Phase I and II metabolism 
The liver is the primary site of metabolism and receives 80% of its blood supply 
from the gut and so has a high metabolic capacity. Drug metabolism normally takes 
place in two stages. Initially, drugs undergo phase I metabolism. This is usually an 
oxidative process which adds or unmasks a functional group so that the molecule can 
undergo conjugation reactions or phase II metabolism, this makes the drug  
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Table 1.1 Summary of phase I and II reactions. 
more hydrophilic and therefore easier to excrete. The cytochrome P450 (CYP450) 
enzyme family are the most important of the oxidative enzymes responsible for 
phase I metabolism. They are able to metabolise a huge array of structurally diverse 
compounds, where the only common factor is a relatively high degree of 
lipophilicity. Although there are many CYP450 enzymes present in the liver the 
most abundant is CYP3A4 which is responsible for the metabolism of many 
xenobiotics (Gibson, Skett 2001). Although most phase I metabolites are unreactive, 
some are bioactivated to chemically reactive metabolites such as quinone-imines, 
which can cause cell damage and death. 
Following phase I metabolism, many compounds undergo phase II conjugation 
reactions such as glucuronidation, sulfation and acetylation. These reactions involve 
a diverse group of enzymes and the above conjugation reactions are carried out by 
UDP-glucuronyltransferases, sulfotransferases and N-acetyltransferases respectively 
(Jancovaa, Anzenbacherb & Anzenbacherovaa 2010). These reactions generally lead 
Phase I reactions Phase II reactions
Oxidation Glucuronidation/glucosylation
Reduction Sulphation
Hydrolysis Methylation
Hydration Acetylation
Dethioacetylation Amino acid conjugation
Isomerisation Fatty acid conjugation
Condensation
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to a more water soluble compound, for easier excretion in the bile or urine as well as 
the metabolic inactivation of pharmacologically active compounds (Gibson, Skett 
2001). Phase II reactions are not commonly associated with the same bioactivation 
reactions as phase I metabolism, however some phase II metabolites such as 
troglitazone sulphate (Funk et al. 2001b) and acyl glucuronides (Regan et al. 2010) 
have been implicated in the toxicity of compounds. Common phase I and phase II 
reactions are summarised in table 1.1. 
1.4.2 GSH conjugation 
GSH is a tripeptide and is probably the most important antioxidant that is produced 
by cells. It not only neutralises endogenously produced electrophiles and free 
radicals but also bioactivated xenobiotics. GSH is synthesised by the formation of a 
peptide bond between glutamic acid and cysteine, catalysed by γ-glutamylcysteine 
synthetase, then subsequent addition of glycine by GSH synthetase (figure 1.2). It is 
the redox and conjugation reactions that take place on the sulfhydryl group of 
cysteine that are thought to be the most important in its detoxifying actions (Forman, 
Zhang & Rinna 2008). During times of oxidative stress and GSH depletion in the 
cell GSH synthesis can be induced by a variety of transcription factors (Copple et al. 
2008). The transcription factors that control the expression of the enzymes involved 
in GSH synthesis can be induced by the conjugation of GSH to electrophiles. In most 
cell types GSH exists at a concentration of 1-2mM but in hepatocytes the 
concentration may be as high as 10mM (Yuan, Kaplowitz 2008). Due to the high 
levels of GSH in hepatocytes GSH conjugation may occur spontaneously but is more  
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Figure 1.2. GSH synthesis. γ-glutamylcysteine is formed from glutamate and cysteine, 
catalysed by γ-glutamate cysteine ligase. Glycine is then added to γ-glutamylcysteine, a 
reaction that is catalysed by GSH synthetase. Redox cycling between GSH and GSSG 
occurs and is mediated by GSH reductase and GSH peroxidase.  
efficient if carried out by GSH-S-transferases (GSTs). GSTs are located in both 
membrane and cytosolic fractions of the cell. Within the cell it is predominantly 
cytosolic and soluble GSTs that carry out the conjugation of GSH to xenobiotics 
(Salinas, Wong 1999).  GSH can conjugate to a broad spectrum of electrophilic 
species including electrophilic carbon, nitrogen, oxygen and sulphur atoms. As GSH 
exists in such high levels in hepatocytes and because of transcriptional activity, it is 
hard to deplete GSH in cells. Redox cycling of xenobiotics in hepatocytes and 
chronic dosing of drugs can deplete GSH to a level where reactive metabolites may 
react with proteins and nucleic acids (Han et al. 2006). Depletion of intracellular 
GSH also leaves reactive oxygen species (ROS) that are endogenous to the cell, or 
that may have been induced by xenobiotics, free to react with lipid and other 
membranes, leading to cellular damage including lipid peroxidation, protein 
oxidation, DNA oxidation and mitochondrial damage (Toyokuni 1999). GSH exists 
in the cell in both the reduced (GSH) and oxidised (GSSG) forms. The ratio between 
the two forms is important in determining the redox status of the cell (Meister, 
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Anderson 1983). It is the oxidation or conjugation of the reduced form that is 
important for quenching ROS and conjugation of molecules. GSSG can be recycled 
back to GSH by the enzyme GSH reductase. 
1.4.3 Reactive metabolites and covalent binding 
Reactive metabolites normally have a low electron density (electrophiles) and seek 
out molecules with a high electron density to form adducts. Electrophiles can be 
classed as either ‘hard’ or ‘soft’ electrophiles. ‘Hard’ electrophiles have a high 
positive charge density or a formal positive charge, while ‘soft’ electophiles are 
those with a low positive charge density. Examples of soft and hard electophiles can 
be found in table 1.2. Soft electrophiles tend to form adducts with proteins, whereas 
hard electrophiles are more likely to target nucleic acids.. Much of the time soft 
electrophiles can be detoxified through conjugation with GSH (Williams et al. 2002).  
However, if GSH is depleted then reactive metabolites are free to react with proteins. 
This may cause either direct modification of the protein or oxidation of redox-
sensitive thiol or amine groups contained within the protein or may cause an immune 
response.  
Direct modification of proteins such as, for example, inhibition of γ-GCS, GAPDH 
and Ca2+/Mg2+ ATPase (Parmar et al. 1995, Dietze et al. 1997b) will severely impair 
the function of the cell through mitochondrial uncoupling, GSH depletion and 
perturbation of Ca2+ homeostasis (Park et al. 2005). All of these can lead to initiation 
of apoptosis and necrosis in hepatocytes.  
12 
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Table 1.2 Summary of hard and soft electrophiles formed from bioactivation. 
Immunoallergic hepatitis is also observed following covalent binding to proteins. 
Proteins that are modified through covalent binding can be internalised by Kupffer 
cells and presented to helper T-cells. This can result in the formation of cytotoxic T-
cells and antibody producing B lymphocytes. The autoantibodies that are produced 
can initiate apoptosis in cells through TNF and Fas pathways. An example of 
immunoallergic hepatitis is halothane. A significant proportion of patients that 
underwent halothane anaesthesia develop asymptomatic rises in liver transaminases 
but did not develop fulminant liver failure. However, upon repeated exposure to 
halothane the risk of liver failure increases from 1:35,000 to 1:3700 (Park et al. 
2005). Halothane is bioactivated by CYP450 2E1 to a trifluoroacetyl radical, which 
may modify lysine residues in a number of hepatic proteins. This leads to the 
production of autoantibodies against trifluoroacetylated hepatic proteins and 
CYP450 2E1, causing destruction to the hepatocyte (Eliasson, Kenna 1996, Martin 
et al. 1993, Vergani, Mieli-Vergani & Alberti 1980). 
The covalent binding of several compounds to macromolecules has been linked to to 
their toxicity, a selection of some of these compounds and their resulting toxicities 
Soft electrophiles Hard electrophiles
Epoxide Alkyl carbonium ions
Enones Benzylic carbonium ions
Quinone-imines Iminium ions
Quinone methides Aldehydes
Michael acceptors
13 
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are identified in table 1.3. However, covalent binding is not always indicative of 
toxicity and recently studies have been undertaken to try and gain a greater 
understanding of the relationship between covalent binding and toxicity. There are 
two approaches to identifying reactive metabolites that are commonly used within 
the pharmaceutical industry; covalent binding using radiolabelled compound and 
GSH trapping and identification of reactive metabolites through mass spectrometry 
(Baillie, Davis 1993). The first attempt to set a quantitative limit as a guideline for 
industry was a paper by Evans et al (Evans et al. 2004). This set a limit for binding 
at 50pmol equiv/mg protein as a flag for toxicity, however this has not necessarily 
been implemented due to the complex and uncertain relationship between covalent 
binding and toxicity. Although covalent binding of a drug to protein may identify a 
risk due to its bioactivation potential, this risk may not be translated into the clinic. A 
good example of this is the difference between the hepatotoxicity of paracetamol and 
its structural isomer AMAP. Both of these compounds irreversibly bind to cellular 
proteins, in fact at one hour AMAP has greater levels of binding than paracetamol 
although this is reversed at 24 hours (Rashed, Myers & Nelson 1990). This is due to 
the different organelles or macromolecules that the drugs bind to within the cell. 
AMAP binds largely to cytosolic proteins, whilst paracetamol binds predominantly 
to mitochondrial proteins (Tirmenstein, Nelson 1989) that are important in 
mechanisms of cell death. This demonstrates it is not necessarily the amount of 
covalent binding that causes toxicity but where in the cell the drug binds. Attempts 
to determine acceptable levels of covalent binding in pre-clinical testing have led to 
the comparison of covalent binding to the daily dose of the compound (Nakayama et 
al. 2009). This gives a much better correlation between those drugs that cause 
idiosyncratic toxicity and those that bind but do not cause idiosyncratic toxicity, 
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Drug  Reactive 
metabolites  
Activating 
enzyme(s)  
Proteins targeted  Toxicity  References  
Paracetamol  NAPQI  CYP450 1A2, 2E1, 
3A4  
Glutamine synthestase,, glutamate 
dehydrogenase, aldehyde dehydrogenase, 
Mg2+ ATPase, Ca2+/Mg2+ ATPase, 
Na+/K+ ATPase, γ-glutamylcysteinyl 
synthetase, GSH-S-transferase, GAPDH 
Hepatotoxicity  (Gupta et al. 1997)(Bulera et al. 1995) (Dietze et al. 
1997a, Kitteringham et al. 2000)(Park et al. 2005, 
Landin, Cohen & Khairallah 1996, Parmar et al. 
1995, Ozdemirler et al. 1994, Halmes et al. 1996, 
Tsokos-Kuhn et al. 1988)(Corcoran, Chung & 
Salazar 1987) 
Sulfamethoxazole  
(SMX)  
SMX-HA, SMX-
NO, N-chloroSMX, 
3-chloroSMX  
CYP450 2C9  Liver microsomal proteins, neutrophils, 
cellular proteins, keratinocytes, lymphoid 
cellular proteins, HSA, Hb  
Hypersensitivity, 
hepatotoxicity  
(Cribb et al. 1996, Cribb, Spielberg & Griffin 
1995)(Gill et al. 1997)(Manchanda et al. 
2002)(Miller, Trepanier 2002)(Naisbitt et al. 
2002)(Reilly et al. 2000, Summan, Cribb 2002, 
Uetrecht, Shear & Zahid 1993) 
Clozapine  Desmethylclozapine  CYPs, MPO  GSH, MPO, other neutrophil proteins  Agranulocytosis  (Gardner et al. 1998, Zhao Chao Liu, Uetrecht 
1995, Maggs et al. 1995, Pirmohamed et al. 1995, 
Williams et al. 1997, Williams et al. 2000) 
Troglitazone  Benzoquinone, 
quinone-epoxide  
CYP450 3A4 GSH, BSEP  Hepatotoxicity  (Funk et al. 2001b, Funk et al. 2001a, Kassahun et 
al. 2001, Kawai et al. 1997, Kostrubsky et al. 2001, 
Prabhu et al. 2002, Preininger et al. 1999, Tettey et 
al. 2001) 
Halothane TFA CYP450 2E1 CYP450 2E1, protein disulfide isomerise, 
carboxylesterase, calreticulin, GST,  
glucosyl transferase, GRP78, GRP94 
Hepatitis (Martin et al. 1993, Vergani, Mieli-Vergani & 
Alberti 1980, Bourdi et al. 1996, Hayden et al. 
1991, Kenna 1997, Martin et al. 1991) 
Table 1.3. Table of compounds where reactive metabolite formation and subsequent protein binding is known to result in cytotoxicity.
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however, it is well established that a link exists between high doses of compounds 
and toxicity. 
1.5 MITOCHONDRIAL TOXICITY AND DILI 
Drug induced mitochondrial toxicity was first described in 1954, when it was noted 
that CCl4 reduced mitochondrial enzyme activity (Christie, Judah 1954). Since then, 
mitochondrial dysfunction has increasingly been seen as an important mechanism 
through which drugs and their metabolites can cause liver injury. Mitochondria are 
involved in nearly all mechanisms of DILI, either primary mitochondrial toxicity or 
secondarily through initiation of the cell death pathways in which mitochondria are 
instrumental. Mitochondrial toxicity can occur in several ways, many of which have 
distinct hallmarks of toxicity such as steatosis caused by disruption of β-oxidation 
pathways and metabolic acidosis due to perturbation of the mitochondrial respiratory 
chain. 
1.5.1 Mitochondrial physiology and function 
Mitochondria contain two membranes, one of which separates the mitochondria from 
the cytoplasm, whilst the other contains the matrix. In between the two membranes is 
the inter-membrane space (PALADE 1953). The outer membrane is mainly smooth 
and consists of a lipid bilayer that contains cholesterol whilst the inner membrane 
consists of several folds called cristae (PALADE 1953). The number of the cristae 
depends on the mitochondrial function, as although their main function in each tissue 
is to provide cellular energy through adenosine triphosphate (ATP) synthesis, 
mitochondria have a variety of different functions in different tissues (Dykens, Will 
2008). The outer membrane contains mitochondrial porin, which allows the diffusion 
of neutrally charged molecules, cations and selected anions up to a molecular weight 
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of 5000Da into the inter-membrane space, making this very much like the cytosol in 
terms of low molecular weight compounds (Dykens, Will 2008). The inner 
membrane is highly selective and unlike the outer membrane contains the unique 
mitochondrial protein cardiolipin (Houtkooper, Vaz 2008).  
The mitochondria produce 95% of a cells ATP through oxidative phosphorylation 
(OXPHOS). The electron transport chain (ETC) (figure 1.6) consists of four 
complexes that sit in the inner membrane of the mitochondria. Electrons pass down 
the chain from complexes I to IV, and each step is coupled to the expulsion of 
protons across the membrane. This acts as a proton pump catalysed by translocating 
enzymes from the matrix to the intermembrane space, creating the proton motive 
force Δ p. This is a combination of two different potentials that are formed from the 
translocation of the protons; ΔΨ which is a result of the differing distribution of 
electrical charges across the membrane and Δ pH which reflects the difference in 
chemical potential across the membrane.  Δ p then drives mitochondrial ATP 
synthase (or complex V) which is the driving force of ATP synthesis from ADP and 
phosphate (Dykens, Will 2008).  
Mitochondria are also responsible for the β-oxidation of fatty acids, which occurs in 
the mitochondrial matrix. To do this, the fatty acid must be activated by forming a 
thioester link with Coenzyme A (CoA), this is catalysed by CoA synthase which is 
located on the outer mitochondrial membrane. Small and medium chain acyl CoA 
molecules are then able to diffuse across the inner mitochondrial membrane. Longer 
chain molecules are conjugated to a polar carnitine molecule and then transported 
into the matrix through a carnitine shuttle. Once in the mitochondrial matrix the fatty 
acid is broken down by ‘rounds’ of degradation. Each round consists of oxidation by 
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FAD, followed by hydration, then oxidation by NAD+ before the final step of 
thiolysis. 
 
Figure 1.6. A summary of the mitochondrial respiratory chain. For every pair of 
electrons that flow from NADH to oxygen there are 10 protons translocated from the matrix 
to the intermembrane space. The movement of H+ from the matrix into the inter-membrane 
space creates the proton motive force (Δp) made up of two different potentials, the electrical 
potential (ΔΨ) and the chemical potential (ΔpH). The protons then move back into the matrix 
via complex V (ATP synthase). The movement of protons drives complex V to produce ATP 
from ADP. 
This removes two-carbon acetyl CoA molecules sequentially from the fatty acid 
chain until the acyl CoA has all been converted to acetyl CoA. The acetyl CoA then 
enters the citric acid cycle. Some drugs can impair mitochondrial fatty acid oxidation 
(FAO) causing the accumulation of triglycerides in the cytoplasm of hepatocytes 
(Fromenty, Pessayre 1995). 
1.5.2 Mitochondria and cell death  
Cells can undergo cell death via two distinct mechanisms; apoptosis and necrosis. 
Apoptosis is an energy requiring process that results in characterised by cell 
shrinkage, nuclear and cytoplasmic condensation, chromatin fragmentation and 
phagocytosis. Necrosis is a passive form of cell death associated with inflammation, 
cellular and organelle swelling, rupture of the plasma membrane and spilling of the 
UQ
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cellular contents into the extracellular milieu (Orrenius 2004). Activation of cell 
death via apoptosis may result from death receptors signaling from death receptors, 
damaged nuclear DNA, lysosomes or stressed endoplasmic reticulum. Bcl-2-
associated x protein (Bax) then translocates from the cytoplasm to the mitochondria. 
 
Figure 1.4. Mitchondrial mediated apoptosis. Signals from death receptors lead to the 
dimerisation and translocation of Bax so that it is inserted into the outer mitochondrial 
membrane. This triggers cytochrome c release from the mitochondrial membrane. Once in 
the cytosol cytochrome c binds to Apaf-1 forming the apoptosome. This promotes pro-
caspase-9 activation to caspase-9 triggering the caspase cascade resulting in apoptosis. 
 
The BCL-2 family contains both pro-apoptotic and anti-apoptotic proteins. If only a 
few molecules of the pro-apoptotic Bax are present, they are sequestered by Bcl-XL, 
an anti-apoptotic member of the BCL-2 family, allowing the cell to live. However, 
when there are too many Bax molecules to be sequestered, they form dimers and 
insert into the outer mitochondrial membrane causing it to become permeable (Gross 
Death receptor
Bax
Bax Cyt. c
Bcl-2
Cyt. c Apaf-1 Apoptosome Pro-caspase
          9
Caspase-9
Caspase cascade
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et al. 1998, Robertson, Orrenius 2000). This allows cytochrome c release from the 
intermembrane space into the cytosol. Once cytochrome c is in the cytosol it 
interacts with apoptosis activating factor-1 (apaf-1), forming the apoptosome which 
triggers the auto-activation of caspase-9 from pro-caspase-9.. Caspase-9 then 
activates the caspase cascade that cuts cytoplasmic and nuclear proteins that leads to 
apoptosis (Li et al. 1997) (figure 1.4). Cytochrome c also activates inositol (1,4,5) 
triphosphate receptors which triggers an efflux of Ca2+ which may enter intact 
mitochondria. An increase in mitochondrial Ca2+ and ROS, through inhibition of the 
mitochondrial respiratory chain, may also cause opening of the mitochondrial 
permeability transition (MPT) pore. In the normal state MPT pores are kept closed 
maintaining ΔΨ, however if the MPT pores open, a massive re-entry of protons leads 
to water accumulation causing the mitochondria to expand and rupture (Robertson, 
Orrenius 2000, Robertson, Orrenius & Zhivotovsky 2000, Crompton 1999). This 
leads to the release of cytochrome c from these mitochondria. If pore opening occurs 
in all mitochondria at once, this causes severe ATP depletion which results in 
necrosis rather than apoptosis. If the MPT pore only opens in certain mitochondria 
the remaining mitochondria are able to continue producing ATP, leading to apoptotic 
cell death (Leist et al. 1997).  
1.5.3 Mechanisms of drug induced mitochondrial injury 
There are several mechanisms by which drugs can cause mitochondrial injury and it 
is likely that this occurs through several, simultaneous mechanisms. Drugs can cause 
mitochondrial dysfunction through direct and indirect mechanisms. 
Some drugs may lead to the opening of MPT pores. The drugs that affect MPT pores 
normally result in ‘cytolytic’ hepatitis, which may lead to fulminant liver failure. 
Although it is poorly understood how drugs can trigger MPT pore opening it is 
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believed that they may directly trigger MPT pore opening such as the NSAID 
diclofenac (Masubuchi, Nakayama & Horie 2002). Other drugs may cause indirect 
opening of the MPT pores through the JNK signalling pathway as with paracetamol 
(Gunawan et al. 2006) or through the increase of cytosolic calcium that enters 
through protein damage caused by the extensive formation of reactive metabolites.  
Other compounds directly influence OXPHOS. Cationic, amphiphilic drugs such as 
amiodarone and perhexiline can first be protonated in the intermembrane space of 
the mitochondria resulting in their transport across the mitochondrial membrane 
potential (ΔΨ). This transfer across the membrane dissipates ΔΨ and increases the 
basal respiration. Carboxylic acids such as NSAIDs, and other acids can also 
uncouple OXPHOS and are known as anionic uncouplers. These anionic uncouplers 
exist as an uncharged species which can easily cross the cross the lipid bilayer of the 
inner mitochondrial membrane (Dykens, Will 2008). Once they have reached the 
more alkaline matrix they dissociate into their anionic form and a proton. The 
anionic form is then extruded into the intermembrane space where a neutral molecule 
is formed once more, which can then undergo another cycle of transportation. This 
again dissipates the membrane potential causing electrons to flow through the ETC, 
bypassing ATP synthase, hence no ATP is produced. Severe uncoupling can 
therefore decrease cellular ATP content  causing mitochondrial dysfunction and cell 
death (Labbe, Pessayre & Fromenty 2008). OXPHOS uncoupling may also occur 
through direct inhibition of the ETC, although little is known about this mechanism 
of mitochondrial injury. 
Fatty acid oxidation (FAO) can be impaired in different ways by different drugs. 
Some drugs can directly impair mitochondrial FAO by inhibiting FAO enzymes or 
by sequestering the FAO cofactors, L-carnitine and coenzyme A (Becker, Harris 
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1983, Corkey et al. 1988). ETC inhibition can also lead to FAO impairment by 
decreasing the regeneration of the oxidised cofactors which are required for β-
oxidation. Severe inhibition of mitochondrial β-oxidation can lead to microvesicular 
steatosis, which is characterised by the presence of many small lipid droplets in the 
cytoplasm of hepatocytes. A less severe but chronic inhibition can cause 
macrovesicular steatosis, a single, large lipid vacuole in the cytoplasm of 
hepatocytes. In the short-term this is normally a benign liver lesion, but can result in 
steatohepatitis if the problem persists over several years (Fromenty, Berson & 
Pessayre 1997). 
1.6 HEPATIC TRANSPORTERS AND DILI 
Hepatic transport proteins are becoming increasingly recognised as a site that drugs 
and/or their metabolites are able to interact with possibly leading to toxic response. 
Basolateral transporters are important in the transport from the blood, whereas 
canalicular transporters are involved in the elimination of drugs and bile acids across 
the canalicular membrane and into the bile. Phase II metabolism generally renders 
the drug too hydrophilic to diffuse across the canalicular membrane into the bile or 
across the hepatic basolateral membrane into sinusoidal blood, carrier-mediated 
transport is therefore required to cross out of the hepatocyte.  
1.6.1 Drug transporters in the liver 
The major drug transporters in cell membranes belong to two superfamilies, the 
ATP-binding cassette (ABC) family, which are involved in primary active transport, 
and the solute carrier (SLC) family of transporters, which is involved in secondary 
active transport (Scherrmann 2009). The ABC transporters use ATP as an energy 
source to transport the molecule, while the SLC transporters are co-transporters and 
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use an ion and/or voltage gradient to transport both ions and solutes together. The 
transporters have broad overlapping substrates and drugs may be transported by 
many different proteins (fig 1.5). Influx transporters in the liver belong to the SLC 
superfamily and includes the four most defined transporter families. This includes 
sodium-dependent taurocholate cotransporting protein (NTCP), which recognises 
drugs with a similar structure to bile acids or drugs that are bound to taurocholate. 
The organ anion transporting polypeptides (OCTPs) and the organic anion 
transporters (OATs) also belong to this superfamily and are mainly responsible for 
the transport of organic anions. Organic cation transporters (OCTs) are the last of 
these families and are specific transporters for organic cation transport. These 
families mainly reside in the sinusoidal membrane and uptake xenobiotics from the 
blood and into the liver.  
The efflux transporters, with the exception of MATE1, belong to the ABC 
superfamily and help with the removal of drugs from hepatocytes into the blood or 
bile. The major ABC transporters that are responsible for pumping substrates back 
into the blood belong to the family of multi-drug resistance associated proteins 
(MRPs). MRP1, MRP3, MRP4, MRP5 and MRP6 reside on the lateral membrane 
and are all involved in efflux transport back to the blood. On the canilicular 
membrane, MRP2 effluxes drugs into the bile. The multi-drug-resistance proteins 
(MDRs) can also be found here including P-glycoprotein (P-gp or MDR1) and 
MDR3, breast cancer resistance protein (BCRP) can also be involved in the transport 
of substrates. The bile salt export pump (BSEP) is also present on the canalicular 
membrane and mainly mediates the biliary excretion of substrates. 
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Drugs such as cyclosporine may inhibit several influx and efflux transporters such as 
OATP1B3, OATP2B1, P-gp and MRP2, which causes potential drug interactions 
particularly with the statins. 
 
Figure 1.5. Influx and efflux transporters in hepatocytes. Influx transporters are highlighted in blue. Efflux transporters that transport substances into the sinusoid are in purple and efflux transporters that transport substances into the bile are in green. 
 
1.6.2 Bile acid transport and DILI 
NTCP accounts for the uptake of 80% of bile acids into hepatocytes from the blood 
and transports both conjugated and unconjugated bile acids (Nicolaou et al. 2012). 
OATPs are also involved in the uptake of bile salts into the hepatocyte Whereas 
multiple bile transporters uptake bile acids from the blood into the hepatocytes the 
main transporter involved in the efflux of bile acids is the bile salt export pump 
(BSEP) (Stieger, Meier & Meier 2007). Although BSEP is not thought to be 
Bile
Blood
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involved in the transport of phase II drugs into the bile numerous xenobiotics have 
been recorded as inhibiting BSEP function. Bile acids in high concentrations are 
themselves hepatotoxic and therefore inhibition of BSEP can cause toxicity through 
accumulation of bile acids (Palmeira, Rolo 2004). An example of this is troglitazone, 
which was withdrawn from the market following cases of severe hepatotoxicity. The 
phase II metabolite of troglitazone, troglitazone sulphate, is excreted from the liver 
into the bile via Mrp-2. If Mrp-2 does not remove the troglitazone sulfate then it can 
accumulate in the liver where it can reach concentrations that inhibit BSEP hence 
causing an increase in bile acids and hepatotoxicity (Funk et al. 2001b, Funk et al. 
2001a, Kostrubsky et al. 2001). 
1.7 NEFAZODONE 
Nefazodone is an antidepressant that 
was first marketed in 1994. A 
phenylpiperazine derivative, it was 
chemically unrelated to other anti-
depressants available on the market, the serotonin re-uptake inhibitors (SSRIs), 
monoamine oxidase (MAO) inhibitors and the tricyclic antidepressants (TCAs). Its 
mechanism of action is thought to be through inhibition of serotonin and 
noradrenalin re-uptake by antagonising the post-synaptic 5-HT2 and α1-drenergic 
receptors (Davis, Whittington & Bryson 1997). The daily dose of nefazodone was up 
to 600mg/day, typically divided into two doses of up to 300mg. In 2004 it was 
voluntarily withdrawn from the market by Bristol-Myers Squibb after rare but severe 
incidences of hepatotoxicity prompted the FDA to issue nefazodone with a black box 
warning. 
O
N N
N
O
N
ClN
Figure 1.6. Structure of nefazodone 
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1.7.1 Nefazodone induced hepatotoxicity 
The black box warning on the nefazodone label estimated the rate of liver failure as 
1 case in 250,000-300,000 patients per year, a rate of three to four times the 
background rate of liver failure (Food and Drug Administration 09/01/2002). The 
FDA has also received reports of at least 55 cases of liver failure, including 20 
deaths and another 39 cases of less severe liver injury. Case studies indicated that 
patients presented with nefazodone induced liver injury 1 month to 2 years following 
initiation of nefazodone treatment. Symptoms of nefazodone induced liver injury 
included jaundice, raised liver enzymes and malaise. Liver biopsy demonstrated 
cholestasis, cirrhosis, fibrosis and centrilobular necrosis (Aranda-Michel et al. 1999, 
Lucena et al. 1999). It was thought that an immune-mediated reaction to the drug 
was unlikely. 
1.7.2 Metabolism and bioactivation of nefazodone and its involvement in 
DILI 
In humans nefazodone is primarily metabolised through hepatic and intestinal 
CYP450 3A4 (Rotzinger, Baker 2002b) before being excreted into the bile. Several 
stable circulating metabolites have been identified in humans including meta- 
chlorophenylpiperazine (mCPP), hydroxynefazodone and a triazoledione metabolite 
(Franc et al. 1991). It has been shown that both hydroxynefazodone and mCPP have 
pharmacological properties, with hydroxynefazodone having affinity similar to the 
parent compound for 5HT2A receptors with both having similar affinity at serotonin 
reuptake sites (Eison et al. 1990). Nefazodone has a bioavailability of approximately 
20% and peak plasma concentrations are reached at approximately 1 hour after 
dosing (Barbhaiya, Dandekar & Greene 1996).  
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Nefazodone metabolism via CYP3A4 has been shown to be extensive, with over 20 
oxidative metabolites identified in human liver microsomes (HLMs) alone (Li et al. 
2007). The metabolism of nefazodone has been implicated in its toxicity. Two 
quinone-imines, benzoquinone and several iminium ions have been identified as 
possible oxidative metabolites of nefazodone through the trapping of reactive 
metabolites using GSH and cyanide (Kalgutkar et al. 2005b, Bauman et al. 2008b, 
Argoti et al. 2005). This implicates a mechanism of toxicity mediated through 
covalent binding of reactive metabolites of nefazodone in the liver as a cause for 
 
Figure 1.7. Bioactivation of nefazodone to reactive metabolites. Nefazodone is 
metabolised by CYP450 3A4 to p-OH-nefazodone, which can then be bioactivated via 2 
electron addition to reactive quinone-imine species. This can then be further metabolised to 
benzoquinone. The quinone-imines that are formed can be trapped using GSH and identified 
using mass spectrometry. Nefazodone can also be metabolised to reactive iminium ions that 
can be trapped using cyanide. Adapted from Argoti et al, 2005. 
 
Cl
NNN
N
N
O
O
N
ClN
OH
N
ClN
O
ClO
O
N
NH
N
ClN
OH
GS
ClHO
OHGS
N
N
N
N
CN
Nefazodone
Iminium
Quinone-
imine
Benzoquinone
P4503A4
P4503A4
GSH
GSH
KCN
27 
 
General introduction 
toxicity. Nefazodone displays binding in both HLMs and human hepatocytes, 
however, as nefazodone is so rapidly turned over covalent binding only represents a 
small amount of metabolism (Bauman et al. 2009, Obach et al. 2008, Obach et al. 
2008). Despite the detection of reactive metabolites and their subsequent covalent 
binding there has never been a study that provides a definitive relationship between 
reactive metabolite formation and toxicity. 
1.7.3 Parent compound and its involvement in DILI 
 Although nefazodone reactive metabolites have been identified, the parent 
compound has also been linked to hepatotoxic effects. Nefazodone has been 
implicated as a mitochondrial toxin and has also been shown to inhibit efflux 
transporters in vitro, particularly inhibition of the bile salt export pump (BSEP).  
Nefazodone has been shown to inhibit complex I of the respiratory chain with an 
IC50 of 14µM. A dose response curve of nefazodone in HepG2 cells grown in 
galactose media, which are more susceptible to mitochondrial toxicity, had an IC50 
value of 9µM compared to 38.4µM in HepG2 cells grown in high glucose media. 
Nefazodone also resulted in significant cell loss, increased ROS and near 
abolishment of mitochondrial membrane potential at 100X its Cmax value for a 
single therapeutic dose (92µM) in sandwich cultured hepatocytes (Dykens et al. 
2008). 
Nefazodone has also been shown to inhibit membrane vesicles expressing BSEP 
with an IC50 of 9µM. A similar effect was also observed in sandwich cultured human 
hepatocytes where nefazodone exhibited a concentration dependent inhibition of 
taurocholic acid transport into the canaliculi (IC50 14µM).  Rats that were orally 
dosed with 75mg/kg showed mean bile acid increases of 167% in the serum one hour 
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(approximate Tmax of nefazodone) after administration, demonstrating the potential 
of nefazodone to cause inhibit bile acid transport. As membrane vesicles without the 
capacity for metabolism and sandwich hepatocytes demonstrated similar IC50 values, 
it was assumed that parent drug rather than a metabolite was responsible for the 
inhibition that was observed. The authors checked for toxicity with and without the 
presence of 1mM 1-aminobenzotriazole (ABT). Treatment with nefazodone 
following ABT pre-incubation resulted in a 45% decrease in total protein synthesis 
whereas nefazodone alone demonstrated full recovery after 24 hours (Kostrubsky et 
al. 2006). This implied that nefazodone itself is more toxic than its metabolites. 
However, this study did not investigate the role of metabolism in hepatocytes and 
whether inhibition re-routed metabolism. Another study into bile acids in sandwich 
cultured hepatocytes demonstrated that nefazodone may inhibit both influx and 
efflux transporters and accumulation of deuterium labelled taurocholic acid in the 
hepatocytes was similar to control values (Ansede et al. 2010).  
1.8 BUSPIRONE 
Buspirone is an azaspirodecanedione 
anxiolytic agent (Eison, Temple 1986). It 
differs from the benzodiazepines, a 
commonly used class of anxiolytics, in 
both structure and pharmacological properties (Eison, Temple 1986). Several studies 
have shown that buspirone binds with high affinity to the 5-HT1A receptor (Eison et 
al. 1986, Taylor, Allen & Becker 1984), however, it has a slow onset of action 
implying a more complex mechanism of action. Buspirone has also been shown to 
have moderate affinity for brain D2-dopamine receptors.  Buspirone has no 
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Figure 1.8. Structure of buspirone 
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significant affinity for benzodiazepine receptors and does not affect GABA binding 
in vitro and in vivo and as such, is used preferentially to the benzodiazepines as it 
does not use produce the same side-effects of sedation and motor impairment 
(Goldberg 1984).  
Buspirone is administered up to 60mg/day, normally as up to 30mg twice daily. It 
undergoes extensive first pass metabolism resulting in a bioavailability of only 4% 
(Gammans, Mayol & Labudde 1986). It has been shown to undergo extensive 
hepatic metabolism via CYP450 3A4. Work by Kerns et al identified 25 metabolites 
in rat bile, urine and S9 fractions using LC-MS analysis (Kerns et al. 1997) and 
studies in human liver microsomes (HLMs) have demonstrated that buspirone is 
metabolised predominantly by CYP3A, with three major routes of metabolism being 
identified as hydroxylation, N-dealkylation and N-oxidation (Zhu et al. 2005). It has 
been demonstrated that some of the metabolites of buspirone are potentially 
pharmacologically active. Its N-dealkylation product, 1-pyrimidinyl-piperazine (1-
PP) is known to possess pharmacological activity in rodents where it is responsible 
for approximately a quarter of the activity of buspirone. Patients do not however, 
exhibit high levels of 1-PP, so this may not be relevant in humans.  
Despite not having any reports of organ-directed toxicity, buspirone demonstrates 
NADPH-dependent covalent binding to human liver microsomes and human 
hepatocytes in the same order of magnitude as nefazodone, which has a similar 
metabolic pathway (Bauman et al. 2009, Obach et al. 2008). Despite the fact that 
buspirone is metabolised to a para-hydroxy metabolite similar to nefazodone, it 
seems that buspirone is devoid of the same bioactivation potential and reactive 
metabolites of buspirone have not been identified (Kalgutkar et al. 2005b).  
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1.9 BIGUANIDES 
Extracts of Galega officinalis (French lilac) have 
been used to treat symptoms resembling those of 
diabetes for many centuries (Witters 2001). In 
1918 guanidine was shown to possess 
hypoglycaemic activity in animals, but it was too 
toxic for use. The less toxic extract galegine, 
began to be used as an anti-diabetic in the early 
1920s. Synthalin A and B, synthetic diguanidines, 
were found to be tolerated and used clinically in 
favour of galegine until the early 1930s when 
insulin use was becoming more common. During 
the 1920s several biguanide derivatives were synthesised but it was not until 1957 
that metformin and phenformin came to the market, followed a year later by 
buformin (Witters 2001). Phenformin and buformin were found to be more potent 
than metformin and therefore were most commonly used.  
The biguanides have multiple impacts upon glucose regulation by decreasing 
intestinal glucose absorption and hepatic glucose efflux, and enhancing peripheral 
insulin response. Due to their pleotropic actions, numerous mechanisms of action 
have been reported in the literature including: inhibition of mitochondrial respiration 
(El-Mir et al. 2000), reduction of oxidative and nitrative stress (Fujita et al. 2010, 
Zou et al. 2004), repression of mitochondrial permeability transition and activation 
of AMP-activated protein kinase (Hawley et al. 2002, Musi et al. 2002, Zhou et al. 
2001).  
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Recently it has been established that AMPK-activators, such as phenformin, have 
potential as anti-cancer agents. It has been recommended that phenformin enters 
clinical trials for the treatment of triple negative and ER-positive breast cancer 
(Caraci et al. 2003, El-Masry, Brown & Dobson 2012). 
1.9.1 Biguanides and lactic acidosis 
Figure 1.10. Mechanisms that may contribute to phenformin induced lactic acidosis. 
The accumulation of phenformin in the liver through accumulation via OCT1 transporters 
and poor metabolisers of phenformin may lead to increased serum and hepatic concentration 
of phenformin. Increased hepatic concentrations could then lead to increased mitochondrial 
accumulation of phenformin via the mitochondrial membrane potential. This could then 
impair mitochondrial function in the liver leading to lactic acidosis. 
Unfortunately, phenformin and buformin were associated a high incidence of lactic 
acidosis (lactate levels greater then 5mmol/L and serum pH of less than 7.35). The 
estimated rate of lactic acidosis induced by phenformin is 40-64 cases per 100,000 
person years (Bailey 1992). The risk of lactic acidosis associated with metformin is 
substantially lower at 3.3 cases per 100,000 patient years, a rate that is also lower 
OCT1 
Accumulation in the liver via OCT1. The
biguanides have been shown to accumulate in
the liver when compared to the plasma.
Metformin accumulates approximately 4-fold
whereas phenformin may accumulate over 60-
fold. The liver has been identified as the place
where elevated lactate levels are likely to
originate from.
Accumulation in the mitochondria. As
buformin and phenformin are lipophilic
cations they are capable of accumulating
against a proton gradient, via ΔΨ, into the
inner membrane of the mitochondria,
dissipating the mitochondrial membrane
potential. They may also inhibit complex I of
the mitochondrial respiratory chain and
interrupt intracellular calcium signalling.
Polymorphism of metabolising enzymes. It has
been demonstrated that phenformin is
metabolised by CYP450 2D6, which is highly
polymorphic. Some patients are unable to
metabolise the drug, leading to higher plasma
phenformin levels and higher lactate levels
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than sulfonylurea use (4.8/100,000 patient years) (Lalau 2010) and untreated 
diabetics, where the incidence of lactic acidosis is 9-16 per 100,000 patient years 
(Brown et al. 1998). Due to this, buformin and phenformin were withdrawn from 
most markets in 1977, however, phenformin is still available in Italy, Greece, Brazil, 
Poland, Portugal, China and Uruguay, where cases of phenformin induced lactic 
acidosis do still occur. Cases of phenformin induced lactic acidosis may also occur in 
other countries, where it has been found as a base in Chinese herbal medicines 
(Ching et al. 2008). Due to the low incidence of lactic acidosis associated with 
metformin it is still widely used, particularly in obese patients and in combination 
with the sulfonylureas, and has become a leading treatment for non insulin 
dependent diabetes mellitus (NIDDM) worldwide. 
 The toxicity of the biguanides may be related to their mitochondrial mechanisms of 
action. The biguanides are known to accumulate in the liver. In rats the metformin 
concentration in the liver was 4 times that in the plasma and for phenformin the 
concentration in the liver was 61 fold higher than in the plasma (Sogame et al. 2011). 
Buformin also accumulates in the liver and studies in humans have showed that 
buformin accumulated up to 25-fold in the liver after an i.v. dose and accumulation 
was even higher following oral administration (Lintz, Berger & Aenishaenslin 1974). 
This accumulation is due to active transport of the biguanides into the liver via the 
organic cation transporter 1 (OCT1). In studies using Oct1(-/-) mice, distribution of 
metformin to the liver was 30 times lower than OCT1 (+/+) mice (Wang et al. 2002). 
Using OCT 1(-/-) versus OCT1 (+/+) mice, the liver has also been identified as the 
organ most likely to be associated with the onset of lactic acidosis (Wang et al. 
2003a). Not only do the biguanides accumulate in the liver but there is evidence that 
they may also accumulate in the mitochondria. The biguanides exist almost entirely 
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in their cationic form at physiological pH. Phenformin, as a lipophilic cation may 
therefore undergo accumulation into the mitochondria against a proton gradient via 
ΔΨ up to 100-fold surrounding cytoplasm concentrations (Davidoff 1971). A 
combination of mitochondrial accumulation and hepatic accumulation could mean 
that the concentrations seen in liver mitochondria are hundreds of fold higher than 
plasma concentrations.  
In man the biguanides are mainly excreted renally and as such are contra-indicated in 
patients with renal disease. There have been no metabolites of metformin or 
buformin identified in man, however, the phenyl ring of phenformin can undergo 
hydroxylation to 4-hydroxyphenformin and its corresponding O-glucuronide (Guest, 
King & Parke 1979, Alkalay, Volk & Roth 1979). The oxidative metabolism of 
phenformin is carried out by CYP450 2D6, which is highly polymorphic in nature 
and approximately 7% of Caucasians are poor metabolisers of CYP450 2D6 
substrates. Studies have identified that phenformin plasma concentrations are 
significantly higher in patients who were also poor metabolisers of debrisoquine 
(Shah et al. 1980, Oates et al. 1982, Bosisio, Galli Kienle & Galli 1981) (another 
CYP450 2D6 substrate) and after a single dose of phenformin, patients had higher 
plasma lactate levels than extensive CYP450 2D6 metabolisers (Idle et al. 1981).  
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1.10 TOOLS USED TO INVESTIGATE METABOLISM AND TOXICITY 
 
1.10.1  Inhibitors used to investigate mechanisms of toxicity 
 
Figure 1.11. Chemical structures of compounds used to inhibit metabolism 
potential drug-drug interactions. 
 
Chemical inhibitors of metabolism are a useful tool in determining the metabolic 
pathways of compounds and the effect that inhibition of a pathway can have on cell 
physiology. A number of chemical inhibitors have been used in this work. Their 
chemical structure is shown in figure 1.11 and their mechanism of action is described 
below. 
ABT is a non-specific suicide inhibitor of CYP450 enzymes, and works through 
autocatalytic alkylation of the CYP450 prosthetic haem group resulting in an N-N-
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bridged benzyne-protoporphyrin IX adduct. ABT has been extensively used to 
inhibit CYP450s in a range of in vitro and in vivo studies.  It is commonly used in 
vitro at a concentration of 1mM with a 30 minute pre-incubation, which results in 
approximately 80% inhibition of total CYP450 activity. Although ABT is a non-
specific inhibitor it has greater specificity for some CYP450s than others, and whilst 
it is thought to almost completely inhibit CYP450 3A4 and CYP450 2A6, it shows a 
lack of inhibition of CYP450 2C9 (Linder, Renaud & Hutzler 2009). 
Ketoconazole is a specific inhibitor of CYP450 3A isoforms at concentrations lower 
than 5µM, although it also has some activity at CYP450 2C9 at low concentrations. 
It has a mixed-competitive type of inhibition and it has previously been shown that 
pre-incubation of ketoconazole with microsomes does not result in increased 
inhibition as with non-competitive inhibitors (Greenblatt et al. 2011). 
Methimazole has been identified as a competitive inhibitor of flavin-containing 
mono-oxygenases (FMOs). FMOs commonly carry out oxidation reactions at 
nucleophilic groups such as the nitrogen atoms in amines and amides. However, 
despite its use as an inhibitor of FMOs it has also been shown to inhibit some 
CYP450s at low concentrations (Guo et al. 1997). 
Whilst quinidine has been shown to be a potent and selective competitive inhibitor of 
CYP450 2D6 in humans, it is much less potent against CYP450 2D2, which is the 
most abundant CYP450 2D isoform in rats. However, quinine, its optical isomer has 
been found to inhibit CYP450 2D in rat hepatocytes at a concentration of 100µM, 
whilst the IC50 in hepatocytes is reported to be 300µM for both compounds. Both 
quinine and quinidine have also been identified as inhibitors of isoforms of UGT and 
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hence can also inhibit the glucuronidation of some compounds (Kobayashi et al. 
1989). 
1.10.2 Stains and dyes for investigating cell toxicity 
 
Fluorescent microscopy is becoming a valuable tool for assessing the actions of 
drugs on cell physiology and viability. A number of these dyes have been used in 
this work and they are described below. Their excitation and emission spectra can be 
seen in table 1.4. 
Table 1.4. Excitation and emission wavelengths for fluorescent dyes used. 
Hoechst 33342 is a nuclear stain which binds to the minor grooves of DNA, with a 
preference for adenine and thymine rich sequences. It is cell permeable and binds 
DNA in both alive and dead cells and can therefore be used to identify the position 
of cells when using fluoroscopy. Hoechst 33342, can also be used as an indicator of 
cell death in non-dividing cells, such as hepatocytes, as it fluoresces brighter as the 
nucleus condenses and the DNA becomes more compact. 
Tetramethylrhodamine methyl ester (TMRM) is a cell permanent, cationic, red-
orange dye that is sequestered into active mitochondria via the mitochondrial 
membrane potential. TMRM only fluoresces when it reaches the mitochondrial 
Name Excitation (nm) Emission (nm)
Hoechst 33342 350 461
TMRM 545 580
TOPRO-3 iodide 642 661
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matrix due to the difference in pH and is therefore an indicator of the presence of a 
mitochondrial membrane potential. 
TOPRO-3 iodide is a carbocyanine monomer nuclear acid stain. It can be used as a 
live dead indicator due to its impermeability to cell membranes. 
 
Figure 1.12. Representative composite image of rat hepatocytes stained with Hoechst 
33342, TMRM and TOPRO-3 iodide.  Blue identifies nuclear staining with Hoechst 
33342. Red shows TMRM staining in active mitochondria and green for the nuclear stain 
and alive/dead indicator TOPRO-3 iodide.  
1.11 AIMS 
The first two experimental chapters in this thesis describe investigations into the 
metabolism, irreversible binding and toxicity of nefazodone compared to that of 
buspirone. The aims of this section of work are: 
• To assess reactive metabolite formation from nefazodone and buspirone. 
• To assess the irreversible binding of nefazodone and buspirone. 
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• To assess the species differences between nefazodone toxicity and 
metabolism in rat and human samples. 
• To investigate the relationship between the metabolism, irreversible binding 
and cytotoxicity of nefazodone. 
The final experimental chapter describes work conducted to examine the metabolism 
of phenformin and whether inhibition of this has an effect on cytotoxicity and lactate 
production. The aims of this section of work are: 
• To determine the full metabolic profile of phenformin in rat hepatocytes. 
• To investigate the inhibition of phenformin with CYP450 2D inhibitors. 
• To determine whether inhibiting phenformin metabolism would have an 
effect on cell viability and lactate production. 
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CHAPTER 2 
NEFAZODONE AND BUSPIRONE: REACTIVE 
METABOLITE FORMATION AND IRREVERSIBLE 
BINDING IN LIVER MICROSOMES 
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2.1 INTRODUCTION 
 
Liver microsomes have long been used to assess the possible bioactivation potential 
of compounds, either through GSH conjugation or irreversible binding studies in the 
presence and absence of NADPH. The bioactivation of compounds to reactive 
metabolites is well documented in the literature and many of the drugs which cause 
DILI are associated with bioactivation. There are several chemical moieties that are 
liable to undergo bioactivation, which are known as structural alerts. These structural 
alerts include anilines and analides, arylacetic and arylpropionic acids, hydrazines 
and hydrazides, thiophenes, nitroaromatics, quinones and quinone-methides 
(Kalgutkar et al. 2005a). 
Nefazodone is an antidepressant that was withdrawn from the market in 2004 
following a black box warning for hepatotoxicity. The hepatotoxicity of nefazodone 
is thought to be mediated through the formation of a reactive quinone-imine via 
para-hydroxylation of the 3-chlorophenylpiperazine moiety, which has been 
identified through GSH conjugation (figure2.1) (Kalgutkar et al. 2005b, Bauman et 
al. 2008a, Argoti et al. 2005, Kalgutkar et al. 2005b). The quinone-imine is then 
postulated to go on to cause hepatotoxicity through irreversible binding to 
macromolecules and oxidative stress. The model hepatotoxin, paracetamol, also 
forms a very well characterised quinone-imine, N-acetyl-p-benzoquinone-imine 
(NAPQI). NAPQI has been shown to cause toxicity through depletion of cytosolic 
and mitochondrial GSH, followed by irreversible binding to important cellular 
proteins, as well as perturbations in cellular Ca2+ homeostasis and mitochondrial 
function leading to cell death. Other compounds that are known to be bioactivated  
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Figure 2.1 Nefazodone bioactivation scheme. Nefazodone has the potential to be 
bioactivated via CYP450 3A4 to both quinone-imine and iminium reactive metabolites, 
which can be trapped by GSH and KCN respectively. 
 
via CYP450 enzymes to quinone-imines are diclofenac and indomethacin. The 
structures of these enzymes can be found in table 2.1. 
Nefazodone has also been demonstrated to irreversibly bind to hepatic proteins in 
human liver microsomes, human S9 fraction and human hepatocytes  
(Nakayama et al. 2009, Bauman et al. 2009, Obach et al. 2008) and it is therefore 
thought that nefazodone toxicity is mediated through the irreversible binding of 
nefazodone to cellular proteins.  
The metabolism of nefazodone is predominantly mediated by CYP450 3A4 
(Kalgutkar et al. 2005b, Rotzinger, Baker 2002a), although further metabolism of the 
circulating metabolite 3-chlorophenylpiperazine has been noted to be mediated 
through CYP450 2D6 (Von Moltke et al. 1999b). Nefazodone is also an inhibitor of 
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CYP450 3A4 leading to several known drug interactions (Abernethy et al. 2001, 
Ashton, Wolin 1996, Helms-Smith, Curtis & Hatton 1996, Von Moltke et al. 1999a) 
as well as auto-inactivation  
Table 2.1. Drugs known to undergo bioactivation to reactive a quinone-imine. Drugs 
such as paracetamol, nefazodone, diclofenac and indomethicin are known to undergo 
quinone-imine formation either directly or indirectly following metabolism to a para-
hydroxy metabolite. 
of its own metabolism leading to non-linear pharmacokinetics (Kaul, Shukla & 
Barbhaiya 1995). 
In contrast to nefazodone, buspirone has no reports of specific organ directed 
toxicity. It is also metabolised through CYP450 3A4 (Zhu et al. 2005) and has the 
potential to be bioactivated through para-hydroxylation on the 1-
pyrimidinylpiperazine moiety. However, no GSH conjugates of buspirone have been 
identified (Kalgutkar et al. 2005b) and it is thought that buspirone is less likely to 
Drug Structure Mechanism of bioactivation References
Paracetamol 2 electron oxidation of para-
acetamidophenol
substructure by CYPs, 
peroxidases and 
cyclooxygenases
Dahlin et al 1984
Corbet et al 1992
Potter and Hinson 
1987
Nefazodone Hydroxylation para to the 
piperazine nitrogen to 
generate para-
hydroxynefazodone which 
undergoes 2 electron 
addition carried out by 
CYP3A4
Kalgutkar et al
Bauman et al
Diclofenac CYP-catalysed 
hydroxylation para to the 
anilide nitrogen to give para
hydroxy diclofenac isomers 
that can undergo CYP or 
peroxidase mediated 
oxidation to quinone-imines
Tang et al 1999
Miyamoto et al 1997
Indomethacin Multipstep process  that 
involves O-demethylation, 
hydrolysis of the N-
acylindole motif and CYP or 
peroxidase mediated 2 
electron addition of the 5-
hydroxyindole metabolite
Ju and Uetrecht 1998
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undergo the two-electron oxidation required to form a quinone-imine. Despite this 
buspirone has been demonstrated to irreversibly bind in both human liver 
microsomes and human hepatocytes (Bauman et al. 2009, Obach et al. 2008). 
The aim of this chapter was to assess the phase I metabolic pathways of nefazodone 
and buspirone in supplemented rat liver microsomes. It also provided the opportunity 
to examine the difference in bioactivation of the two compounds using GSH trapping 
and irreversible binding. Finally the bioactivation of nefazodone was assessed in 
human liver microsomes to confirm the translation of bioactivation in the rat into 
man. 
 
Figure 2.2. Chemical structures of nefazodone and buspirone. * Indicates the position of 
the radiolabel for irreversible binding experiments. 
2.2 MATERIALS AND METHODS 
 
2.2.1 Materials 
Buspirone was purchased from Sigma-Aldrich (Poole, Dorset, UK) and nefazodone 
was kindly purchased by Pfizer from Bosche Scientific (New Jersey, US). [14C]- 
nefazodone and [14C]-buspirone were supplied by Pfizer (Sandwich, Kent, UK). 
Human liver microsomes were donated by Pfizer (Sandwich, UK). Liquid 
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scintillation cocktail Gold Star was purchased from Meridian (Epsom, Surrey, UK).  
MTS reagent and ATP cell viability assay were purchased from Promega (UK). All 
other reagents unless otherwise stated were purchased from Sigma-Aldrich (Poole, 
Dorset, UK). Solvents were purchased from Fischer and were all at least HPLC 
grade. 
2.2.2 Preparation of rat liver microsomes 
Rat liver micrsosomes were prepared from adult male Wistar rats killed by rising 
levels of CO2. The livers were removed and placed into ice-cold 0.067M phosphate 
buffer, pH 7.4, containing 1.15% (w/v) KCl. The livers were then chopped into 
smaller pieces with a pair of scissors, before being homogenised with a motor-driven 
homogeniser. This was followed by homogenisation with a manual homogeniser. 
The homogenate was then centrifuged at 18,000rpm for 25 minutes at 4°C to remove 
any cellular debris. The resulting supernatant was then centrifuged at 35,000rpm at 
4°C to pellet the microsomes. The microsome pellet was then re-suspended by 
manual homogenisation in phosphate buffer with KCl before being centrifuged at 
35,000rpm, for 65 minutes at 4°C. The supernatant was discarded and the 
microsomes re-suspended in phosphate buffer without KCl and stored at - 80°C until 
required. 
2.2.3 Microsomal protein content and CYP450 content 
Microsomal CYP450 content was determined using the procedure described by 
Omura et al (1964). Protein content was determined using a Lowry protein assay 
(LOWRY et al. 1951) and bovine serum albumin was used for the standards. 
2.2.4 Rat liver microsome incubations 
Microsome incubations were carried out in a final volume of 0.067M phosphate 
buffer, pH 7.4 and contained a final concentration of 1mg/ml microsomal protein. 
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All incubations included a final concentration of 5mM MgCl2 and all but control 
incubations contained 1mM NADPH. Incubations for metabolism included a 
concentration of either 100µM nefazodone or buspirone and incubations for covalent 
binding were carried out using 10µM nefazodone or buspirone and 0.1µCi of 
corresponding radiolabelled compound. The samples were incubated in a shaking 
water bath for 60 minutes at 37°C. The reaction was terminated by addition of an 
equal volume of ice-cold ACN and stored at -20°C.  
2.2.5 Rat liver microsome incubations containing trapping agents and 
inhibitors 
Incubations contained either 1mM reduced GSH, 1mM 1-aminobenzotriazole (ABT) 
or 5µM ketoconazole. Incubations containing ABT were pre-incubated for 15 
minutes at 37°C before addition of drug to initiate the reaction. Controls contained 
no NADPH. The samples were incubated for a further 60 minutes before being 
terminated using an equal volume of ice-cold ACN. 
2.2.6 Measurement of irreversible binding using the solvent exhaustion 
method 
Covalent binding of [14C]-nefazodone and [14C]-buspirone was measured using 
exhaustive solvent extraction method. The samples were centrifuged at 2200rpm, for 
10 minutes. 100µl of supernatant was removed for scintillation counting and the 
supernatants were kept for LC-MS analysis. 3ml of 100% MeOH was added to each 
pellet and was vortexed and centrifuged again. 100µl of supernatant was removed 
from each supernatant for scintillation counting and the rest was discarded. 3ml of 
70% MeOH was added to the pellet and vortexed before being centrifuged at 
2200rpm. Again, 100µl was kept for scintillation counting and the rest was 
discarded. This process was repeated once more with 70% MeOH after the 
supernatant was removed and the left over solvent was evaporated in a 60°C oven. 
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1ml NaOH (1M) was then added to each pellet, vortexed and the protein left to 
dissolve. 100µl of this was taken for scintillation counting and the protein content 
was assessed using a Lowry assay (LOWRY et al. 1951). Irreversible binding was 
calculated as pmol equivalent/mg protein. 
2.2.7 Human liver microsome incubations. 
Human liver microsome incubations were carried out in a final volume of 1ml in 
0.067M phosphate buffer, pH 7.4, and contained a final concentration of 1mg/ml 
microsomal protein. All incubations included a final concentration of 5mM MgCl2 
and all but control incubations contained NADPH. The samples were incubated in a 
shaking water bath for 60 minutes at 37°C. For inhibition studies the human liver 
microsomes were pre-incubated for 15 minutes at 37°C with a final concentration of 
1mM ABT or 200µM methimazole with 1mM NADPH. After the pre-incubation 
period a final concentration of 50µM nefazodone and more NADPH was added and 
incubated for a further 60 minutes. All incubations were terminated with an equal 
volume of ice-cold ACN. 
2.2.8 Sample preparation for LC-MS  
Samples were stored overnight at -20°C to allow any protein to precipitate. The 
samples were centrifuged at 2200rpm and the supernatant kept. The supernatant was 
then evaporated under a gentle stream of nitrogen gas. The samples were 
reconstituted in 300µl of 50% MeOH, before being centrifuged at 14,000rpm. The 
supernatant was then analysed using LC-MS or LC-MS/MS. 
2.2.9 LC-MS buspirone 
 
LC-MS analysis was performed on an API 2000. The LC system consisted of an 
Agilent Eclipse XDB C18 column (4.6x150mm, 5µ). The aqueous phase was 15mM 
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ammonium formate (A). The organic solvent (B) was ACN. A gradient separation 
was used starting initially with 10% B rising to 30% B over 35 minutes and held at 
30% for 5 minutes. 25µl of sample was injected onto the column. The flow rate was 
1ml/min and the mass spectrometer operated in positive ion mode. The mass spec 
parameters for buspirone are listed in table 2.2. 
Table 2.2 Operating parameters of API2000 for buspirone analysis. 
 
2.2.10 LC-MS nefazodone in rat liver microsomes 
LC-MS analysis was performed on an API 2000. The LC system consisted of a 
Phenomenex phenyl-hexyl column (4.6x150mm, 5µ) and a Perkin Elmer LC-200 
quaternary pump. The aqueous phase was 15mM ammonium formate (A) and 
organic was ACN (B). A gradient separation was run starting at 5% B rising to 70%  
Table 2.3.Operating parameters of API2000 for nefazodone analysis 
B over 25 minutes. This returned to 5% B at 26 minutes until 30 minutes. The flow 
rate was 1ml/min. Ionisation was conducted in positive ion mode. The mass 
spectrometer parameters can be viewed in figure 2.3. 
Curtain gas (CUR) 30.00
Ion spray voltage (IS) 5000.00
Temperature (TEM) 400.00
Ion source gas 1 (GS1) 30.00
Ion source gas 2 (GS2) 75.00
De-clustering potential 
(DP)
40.00
Focusing potential (FP) 350.00
Entrance potential (EP) 10.00
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2.2.11 LC-MS nefazodone in human liver microsomes 
LC-MS analysis was performed on an API 4000. The LC system consisted of a 
Phenomenex phenyl-hexyl column (4.6x150mm, 5µ) and a Perkin Elmer LC-200 
quaternary pump. The aqueous phase was 15mM ammonium formate (A) and 
organic was ACN (B). A gradient separation was run starting at 5% B rising to 70% 
B over 25 minutes. This returned to 5% B at 26 minutes until 30 minutes. The flow 
rate was 1ml/min and the detection was by positive-ion electrospray ionisation, The 
mass spectrometer parameters can be viewed in table 2.4. 
 
Table 2.4. Operating parameters for API4000 for nefazodone analysis 
CUR 20.00
IS 5000.00
TEM 400.00
GS1 30.00
GS2 75.00
DP 66.00
FP 250.00
EP 11.50
CUR 15.00
IS 4500.00
TEM 400.00
GS1 50.00
GS2 50.00
DP 150.00
EP 10.00
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2.2.12 Animal work 
All animal work was carried out according to local ethics policies and in accordance 
with home office regulation. 
2.2.13 Human ethics 
All work with human samples was carried out in accordance with local ethics 
policies. 
2.2.14 Statistics 
Statistical analysis was undertaken using Stats Direct software. Data was tested for 
normality using a Shapiro-Wilk test and either a Student’s T test (parametric) or 
Mann-Whitney U test (non-parametric) was used to make comparisons between data 
sets. An ANOVA (Dunnett’s comparison to control) was used to determine 
significance to control values. 
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2.3 RESULTS 
2.3.1 Metabolism of buspirone in rat liver microsomes 
 
The metabolism of buspirone (m/z 386) in rat liver microsomes (figure 2.3) 
consisted mainly of hydroxylation reactions. At least 4 [O] buspirone metabolites 
(m/z 402) were identified consisting of those that had been substituted on both the 
pyrimidinyl and azaspirone moieties. This was determined by the shift of m/z 123 to 
m/z 139 through substitution on the azaspirone moiety and a shift of m/z 122 to m/z 
138 indicating hydroxylation on the pyrimidine structure. At least 3 [2O] buspirone 
(m/z 418) metabolites were also identified which contained hydroxylation on both 
the azaspirone and pyrimidinyl moieties. N-dealkylation reactions also took place 
and 1-pyrimidinyl piperazine (m/z 165) and despyrimidinyl piperazine buspirone 
(m/z 254) were also detected. Retention times of the compounds can be found in 
table 2.5. The structures of the metabolites identified in rat liver microsomes can be 
found in figure 2.4. Appendix 1 contains the AUC for each metabolite. In accordance 
with the literature , incubations containing GSH (1mM) did not result in the 
detection of any GSH conjugates of buspirone, despite searching for both addition of 
306 and neutral loss of 129.   
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Figure 2.3. LC-MS traces of buspirone metabolites in rat liver microsomes. (A) Total ion current (B) TIC m/z 386 (C) TIC m/z 402 (D) TIC m/z 418. 
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Name  m/z  Retention time 
(mins)  
1-pyrimidinylpiperazine  165  6.28  [2O] buspirone  418  18.35  [2O] buspirone  418  18.86  [2O] buspirone  418  19.86  [2O] buspirone  418  22.691  [O] buspirone  402  24.03  Despyrimidinyl piperazine buspirone  254  25.86  [O] buspirone  402  26.53  [O] buspirone  402  27.53  [O] buspirone  402  29.62  Buspirone  386  35.2 
Table 2.5. Metabolites of buspirone identified in rat liver microsomes. 
  
54 
 
Nefazodone and buspirone: reactive metabolite formation and irreversible binding in liver 
microsomes 
 
Figure 2.4. Schematic of buspirone metabolites identified in RLMs 
 
2.3.2 Metabolism of nefazodone in rat liver microsomes 
 
Like buspirone, the metabolism of nefazodone mainly consisted of hydroxylation 
(figure 2.4) and N-dealkylation reactions. Nefazodone yielded three [O] nefazodone 
(m/z 486) products (figure 2.6.). Fragment ions of these metabolites indicated that 
these consisted of a metabolite with an m/z 274 and one with a fragment ion m/z 
290. A fragment ion with an m/z 274 indicates an unsubstituted phenoxyethyl-
triazolone-propyl moiety, indicating nefazodone is most likely to be hydroxylated on 
the chlorophenyl ring. This leads to the possibility of the formation of the para-
hydroxy metabolite. Two [2O] nefazodone (m/z 502) products were also identified 
(figure 2.4), although, the location of the additional hydroxyl groups was not 
determined. Metabolites at m/z 484, [=O] nefazodone, and m/z 292, phenoxyethyl-
triazolone n-propanol could also be detected. The hydroxylated metabolite of 
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chlorophenyl piperazine, which has also been reported to undergo bioactivation to a 
quinone-imine was not detected. The retention times of the metabolites can be found 
in table 2.6 and the proposed metabolic structures in figure 2.8. Appendix 2 contains 
the AUC for each metabolite. 
In incubations of nefazodone containing GSH (1mM), two GSH conjugates were 
identified (figure 2.7). The two metabolites had an m/z 807 (GS1) and an m/z 791 
(GS2). GS1, [2O] nefazodone GSH had a very weak signal and was only just 
detectable, however, GS2, [O] nefazodone GSH was more prominent in the sample 
even though it still only appeared to be present in relatively small amounts compared 
to other metabolites. These metabolites correspond with the hydroxylated 
nefazodone products that were formed and suggesting that nefazodone undergoes 
quinone-imine formation in rat liver microsomes. 
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Figure 2.5. Metabolism of nefazodone in rat liver microsomes. (A) Total ion current (B) XIC m/z 470 nefazodone. (C) XIC m/z 486 [O] nefazodone (D) 
XIC m/z 502 [2O] nefazodone. 
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Figure 2.6. Fragmentation of [O] nefazodone metabolites in rat liver microsomes. (A) 
XIC m/z 486 [O] nefazodone. (B) Fragment ions of [O] nefazodone I (C) Fragment ions of 
[O] nefazodone II (D) Fragment ions of [O] nefazodone III. 
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Figure 2.7. GSH conjugates of nefazodone identified in rat liver microsomes. (A) XIC m/z 791 [O] nefazodone GSH conjugate. (B) XIC m/z 807 [2O] nefazodone conjugate. 
 
 
Name  m/z  Retention time (mins)  
[2O] nefazodone  502  15.45  
[2O] nefazodone  502  15.85  
Phenoxyethyltriazolone n-propanol  292  16.19  
[O] nefazodone  486  17.19  
[O] nefazodone  486  17.34  
[O] nefazodone  486  18.34  
Nefazodone  470  20.12  
[=O] nefazodone  484  20.95  
Table 2.6. Metabolites of nefazodone identified in RLMs. 
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Figure 2.8. Metabolic scheme of nefazodone metabolites identified in 
RLMs 
2.3.4 Irreversible binding of nefazodone and buspirone in rat liver 
microsomes 
Both nefazodone and buspirone demonstrated significant NADPH-dependent 
irreversible binding in rat liver microsomes (figure 2.9). Although nefazodone and 
buspirone both displayed irreversible binding, nefazodone exhibited levels of 
irreversible binding 9-fold higher than those of buspirone (105.54 ±12.46 pmol 
equiv/mg protein and 12.76 ± 0.48 pmol equiv/mg protein respectively). Pre-
incubation of the microsomes with ABT reduced the irreversible binding of 
buspirone and nefazodone significantly, so that binding was not significantly 
different from control values. The CYP450 3A4 inhibitor, ketoconazole, was also 
added to incubations. Ketoconazole significantly decreased the irreversible binding 
of buspirone to rat liver microsomal protein when compared to NADPH incubations 
(5.9 ± 0.23 pmol equiv/mg protein), however this was not the case for nefazodone 
(73.54 ± 17.96 pmol equiv/mg protein). Nefazodone and buspirone covalent binding 
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was also significantly decreased when GSH was added to the incubations 
(16.13±2.63 pmol equiv/mg protein and 8.65 ± 0.19 pmol equiv/mg protein 
respectively).   
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Figure 2.9. Irreversible binding of nefazodone (A) and buspirone (B) in rat liver 
microsomes. Data is expressed as pmol equivalent/mg protein and is taken from 3 independent isolations. *P<0.05, **P<0.01, *** P<0.001 versus NADPH. †P<0.05 ††P<0.01 ††† P<0.001versus control. Statistical significance was determined using ANOVA (Dunnett’s comparison to control).  
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2.3.5 Phase I metabolism of nefazodone in human liver microsomes 
 
The metabolism of nefazodone in human liver microsomes was similar to that in rat 
liver microsomes and consisted of hydroxylation (figure 2.10) and N-dealkylation 
reactions. There were also 3 [O] nefazodone metabolites in human liver microsomes 
and as in rat liver microsomes the most polar of these had an unsubstituted 
phenoxyethyl-triazolone propyl moiety (figure 2.11). Unlike in rat liver microsomes, 
however, there was only one [2O] nefazodone metabolite detected, which appeared 
to be hydroxylated on both the chlorophenylpiperazine and the phenoxyethyl-
triazolone propyl moiety. The products of N-dealkylation reactions could also be 
identified.  
In incubations containing GSH (1mM) two GSH conjugates were detected. As in rat 
liver microsomes these were the products of [O] nefazodone and [2O] nefazodone. 
The GSH conjugates were easier to detect in the human liver microsomes which 
allowed for a better fragmentation pattern (figure 2.12). The unsubstituted 
phenoxyethyl-triazolone-propyl fragment of m/z 274 can be clearly seen in the 
fragmentation pattern of the [O] nefazodone GSH conjugate (m/z 791), whilst a m/z 
290 fragment, indicating hydroxylation on both the chlorophenylphenylpiperazine 
and phenoxy-ethyl-triazolone-propyl moieties, can be identified in the [2O] 
nefazodone GSH conjugate (m/z 807).  
 
63 
 
Nefazodone and buspirone: reactive metabolite formation and irreversible binding in liver microsomes 
 
Figure 2.10. Hydroxylated metabolites of nefazodone in human liver microsomes. (A) Total ion current of nefazodone metabolism. (B) XIC m/z 470 nefazodone (C) XIC m/z 486 [O] nefazodone. (D) XIC m/z 502 [2O] nefazodone. 
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Figure 2.11. Fragment ions of [O] nefazodone in human liver microsomes. (A) XIC m/z 
486 [O] nefazodone. (B) Fragment ions of [O] nefazodone I with a fragment ion of m/z 274 
indicating an unsubsituted phenoxyethyl-triazolone propyl fragment. (C) Fragment ions of 
[O] nefazodone II. (D) Fragment ions of [O] nefazodone III.  
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Figure 2.12. GSH conjugates of nefazodone in human liver microsomes. (A) XIC m/z 791 [O] nefazodone GSH conjugate. (B) Fragment ions of the [O] nefazodone GSH conjugate. (C) XIC m/z 807 [2O] nefazodone GSH conjugate. (D) Fragment ions of the [2O] nefazodone GSH conjugate. 
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2.3.6 Effect of inhibitors on the phase I metabolism of nefazodone in 
human liver microsomes 
 
Incubation of nefazodone with the inhibitors ABT and methimazole in human liver 
microsomes led to the decreased metabolism of nefazodone (figure 2.13). Based on 
the ratios to parent compound, it appeared that ABT almost completely abolished 
metabolism. Without the use of a quantitative method it was difficult to determine by 
how much the turnover was reduced, however, the only metabolite that could be 
detected following ABT pre-incubation of the human liver microsomes was a [O] 
nefazodone metabolite. This corresponded with the [O] nefazodone I metabolite 
which has a fragment at m/z 274, making it the [O] nefazodone metabolite that is 
most likely to undergo bioactivation. Despite this the ratio of the peak to nefazodone 
was greatly diminished (0.307 to 0.021) and there is a high probability that in these 
incubations, turnover to [O] nefazodone I was reduced to a great extent.  
Inclusion of methimazole in the incubation reduced metabolism to some degree. It 
reduced turnover to [O] nefazodone metabolites but the main effect was on the major 
peak [2O] nefazodone peak at 17.1 minutes, where the ratio of the peak to the parent 
compound was reduced from 0.245 to 0.027. Methimazole is an inhibitor of human 
FMO and, there is a possibility that the [2O] nefazodone is an N-oxide, due to the 
decrease in the ratio to the parent. As such it is tentatively suggested that the [2O] 
nefazodone metabolite is formed via N-oxidation followed by sequential 
hydroxylation.  
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Figure 2.13. Effect of inhibitors on nefazodone metabolism in human liver 
microsomes. (A) Total ion current nefazodone metabolism in human liver 
microsomes. (B) Total ion current of nefazodone metabolism following ABT pre-
incubation. (C) Total ion current of nefazodone metabolism following pre-
incubation with methimazole. Numbers represent the ratio of the major 
hydroxylate metabolite to the parent peak. 
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2.4 DISCUSSION 
 
The investigations in this chapter aimed to assess the metabolism and bioactivation 
of nefazodone and buspirone in rat liver microsomes and to further assess the 
bioactivation of nefazodone in human liver microsomes. This demonstrated that 
nefazodone formed both GSH conjugates in rat and human liver microsomes and 
also demonstrated significant irreversible binding in rat liver microsomes. In contrast 
buspirone, did not produce any GSH conjugates and although significant irreversible 
binding was noted this was several times lower than that of nefazodone. 
The metabolism of nefazodone and buspirone in liver microsomes mainly consists of 
hydroxylation and N-dealklylation reactions. The hydroxylation of nefazodone is of 
particular interest as it has been suggested that the para-hydroxylation of 
nefazodone, followed by bioactivation is responsible for its hepatotoxicity 
(Kalgutkar et al. 2005b, Bauman et al. 2008a, Argoti et al. 2005). Buspirone, which 
has a pyrimidinylpiperazine ring instead of a phenylpiperazine ring, has also been 
shown to have a para-hydroxy metabolite but has not been shown to be bioactivated 
(Kalgutkar et al. 2005b). Both drugs are metabolised by CYP450 3A4 (Zhu et al. 
2005, Rotzinger, Baker 2002a, Von Moltke et al. 1999a, Kalgutkar et al. 2005a) and 
it is thought that a potential reason for the difference between the toxicity profiles of 
nefazodone and buspirone is due to their differing bioactivation potential.  
Analysis of the metabolism of nefazodone in rat and human liver microsomes 
demonstrated three [O] nefazodone metabolites. One of these had a fragment ion 
with m/z 274, indicating an unsubstituted phenoxyethyl-triazolone-propyl fragment 
and, therefore, hydroxylation on the phenylpiperazine ring. Hydroxylation of 
nefazodone para to the piperazine nitrogen leads to the possibility of two electron 
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oxidation to a reactive quinone-imine. To determine whether a quinone-imine was 
formed, incubations were carried out in the presence of excess GSH to trap the 
reactive metabolite. This identified two GSH adducts, one formed from [O] 
nefazodone and one from [2O] nefazodone, in both rat and human liver microsomes. 
This corresponded with the bioactivation pathway that has previously been identified 
(Kalgutkar et al. 2005b, Bauman et al. 2008b, Argoti et al. 2005). Buspirone also 
produced several hydroxylated metabolites, and it is likely that one of these was a 
para-hydroxy metabolite on the pyrimidinyl piperazine, signified by a shift from m/z 
122 to m/z 138 in the fragmentation pattern. Unlike nefazodone, in the trapping 
experiments no GSH conjugates of buspirone could be identified.  
As the formation of N-oxides of nefazodone has been reported, inhibitor studies with 
the CYP450 inhibitor, ABT, and the FMO inhibitor, methimazole, were undertaken. 
ABT reduced considerably the metabolism of nefazodone and only a [O] metabolite 
could be detected, but this metabolite also produced a less intense peak on the LC-
MS when compared to parent compound. Whilst ABT almost abolished the 
metabolism of nefazodone, the most noticeable effect of methimazole was on the 
peak corresponding to [2O] nefazodone. It is a possibility that the m/z 502 
metabolite is an N-oxide that undergoes subsequent hydroxylation. However, 
although methimazole is widely reported to be an inhibitor of FMOs it has also been 
shown to inhibit CYP450 3A4 (Guo, Z et al. 1997). It is, therefore, not possible to 
state with certainty whether the [2O] nefazodone is a result of N-oxide formation.  
To reinforce the observation that nefazodone can be bioactivated by rat liver 
microsomes whilst buspirone is not, irreversible binding studies were undertaken 
using [14C] nefazodone and buspirone. These studies demonstrated that nefazodone 
and buspirone both exhibit significant NADPH-dependent irreversible binding 
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compared to control values. However, the irreversible binding of buspirone was 9-
fold lower than that of nefazodone. Incubation with the non-specific suicide CYP450 
inhibitor, ABT, significantly attenuated irreversible binding, further providing 
evidence that bioactivation via CYP450 enzymes are involved in the bioactivation of 
nefazodone. As expected, following identification of GSH adducts, GSH also 
significantly prevented the irreversible binding of nefazodone to rat liver microsome 
protein. The specific CYP450 3A4 inhibitor, ketoconazole, significantly reduced the 
binding of buspirone, but not nefazodone. It is possible whilst buspirone is 
metabolised by the same isoform in rat and human, that nefazodone is metabolised 
by either a different CYP450 in rat or a different CYP450 3A isoform than  CYP450 
3A1 which is the main isoform present in rat liver. Several discrepancies between the 
metabolism of rats and humans exist in regards to CYP450 3A. The well known 
CYP450 3A4 inducer rifampicin does not seem to induced CYP450 3A1 (Lu, Li 
2001) and other model substrates of CYP450 3A4 metabolism are not metabolised 
by CYP450 3A1 (Guengerich 1997).  
Quinone-imines, and their subsequent irreversible binding, have been implicated in 
the toxicity of several compounds (table 2.1). As a result the formation of quinone-
imines and irreversible binding in liver microsomes highlights the potential role of 
reactive metabolite formation in nefazodone induced liver injury. The most 
commonly investigated quinone-imine is NAPQI and its formation from paracetamol 
and subsequent covalent binding is well documented. NAPQI has been demonstrated 
to bind to mitochondrial proteins causing disruption of cellular processes and 
activation of cell death pathways. While irreversible binding and the modification of 
cellular proteins by electrophilic reactive metabolites is undoubtedly important in 
eliciting the toxicity of some drugs, the usefulness of in vitro irreversible binding 
71 
 
Nefazodone and buspirone: reactive metabolite formation and irreversible binding in liver 
microsomes 
data to predict the toxicity is debated (Nakayama et al. 2009, Obach et al. 2008, Usui 
et al. 2009). Although a definitive link between the bioactivation of paracetamol, the 
resulting irreversible binding and hepatotoxicity has been well established it is not so 
clear cut for other compounds. In fact the regioisomer of paracetamol, 3’-
hydroxyacetanilide, also undergoes bioactivation to a reactive metabolite and 
displays irreversible binding, but is not hepatotoxic to mice. Irreversible binding 
studies in liver microsomes between hepatotoxic and non-hepatotoxic drugs shows 
that irreversible binding alone cannot distinguish between the hepatotoxic and non-
hepatotoxic compounds. In fact a study by Obach et al showed that the non-
hepatotoxin diphenhydramine exhibits higher irreversible binding in human liver 
microsomes than nefazodone and the hepatotoxin diclofenac (Obach et al. 2008). 
Separation of the groups of compounds cannot be improved by UDPGA or GSH 
(Obach et al. 2008, Usui et al. 2009). Multiplication of the irreversible binding by 
daily dose of the compound improves the distinction between the hepatotoxic and 
non-hepatotoxic drugs, however, it is well documented that the dose of the drug is 
related to toxicity. 
It must also be taken into account that liver microsomes do not possess a full 
complement of metabolising enzymes. Non-microsomal enzymes can play both a 
role in bioactivation and detoxification of reactive metabolites, as such, liver 
microsomes cannot always predict accurately how a drug will be metabolised in 
vivo. For example, raloxifene undergoes CYP450 3A4 mediated bioactivation of its 
phenolic groups in vitro to yield a reactive quinoid species (Chen et al. 2002). In 
vivo, however, glucuronidation of the phenolic groups in the gut and liver contributes 
to the principal elimination mechanism of raloxifene (Dalvie et al. 2008). This may 
explain the low levels of idiosyncratic toxicity observed with raloxifene. 
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From this data included in this chapter we can begin to build a decision tree similar 
to those that are used in industry (figure 2.14). Both of these compounds demonstrate 
significant NADPH-dependent binding when compared to control values, however 
there is a difference in GSH conjugation and dose. Whilst nefazodone forms GSH 
conjugates which are indicative of bioactivation, whilst buspirone does not, it could 
be argued that nefazodone has a clear detoxification pathway via GSH, whereas 
buspirone irreversible binds without a clear detoxification method present. Dose 
must also be taken into account when making any such decisions. The highest dose 
recommended for use with nefazodone is 10-fold that of buspirone and therefore it is 
more likely that buspirone would be taken forward into further testing from these 
investigations. However, based on this data nefazodone would still likely proceed 
with caution as the dose started on is much lower and a decision cannot be made on 
irreversible binding alone. 
In conclusion, nefazodone demonstrated both reactive metabolite formation to 
quinone-imines and irreversible binding in liver microsomes. On the other hand 
although buspirone exhibited significant irreversible binding this was small in 
comparison to nefazodone and no GSH conjugates of buspirone were identified. This 
implies that bioactivation of nefazodone is responsible for its toxicity, however, a 
definitive link between irreversible binding and toxicity cannot be determined from 
liver microsomes alone. To investigate the relationship between bioactivation of  
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Figure 2.14. Overview of bioactivation of buspirone and nefazodone in rat liver 
microsomes.(DeLeve, Kaplowitz 1991)(DeLeve, Kaplowitz 1991) 
 
nefazodone and cytotoxicity, the next chapter (chapter 3) will employ the use of 
primary rat and human hepatocytes. This will provide a complete set of metabolising 
enzymes to explore bioactivation of irreversible binding to a further extent, alongside 
the assessment of cytotoxicity 
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3.1 INTRODUCTION 
 
The previous chapter identified that nefazodone metabolites irreversibly binds to 
protein and that this was significantly reduced when GSH was included in the 
incubation. GSH adducts of nefazodone were also identified in RLMs, therefore, 
identifying reactive metabolite formation as a potential cause of nefazodone 
hepatotoxicity. In contrast to buspirone, irreversible binding was 9-fold lower than 
nefazodone and no GSH conjugates of buspirone were identified, providing evidence 
of the possibility that the differing bioactivation potentials of nefazodone and 
buspirone are responsible for their different safety profiles. This has led to the 
hypothesis that reactive metabolite formation and irreversible binding are 
responsible for the differences in nefazodone and buspirone toxicity. 
The clearance of nefazodone is principally through hepatic and intestinal metabolism 
by CYP450 3A4 (Rotzinger, Baker 2002b, Mayol et al. 1994). Nefazodone is 
extensively metabolised to a number of hydroxy metabolites, and it has been shown 
that following para-hydroxylation, nefazodone can undergo bioactivation to a 
quinone-imine reactive metabolite species (Kalgutkar et al. 2005b, Bauman et al. 
2008b, Argoti et al. 2005). It has also been demonstrated that nefazodone 
irreversibly binds to liver S9 fraction and human hepatocytes (Bauman et al. 2009). 
Although in the previous chapter we concentrated on the GSH adducts of nefazodone 
evidence has been presented to suggest that nefazodone forms an iminium ion as 
several adducts of nefazodone have been identified using cyanide trapping (Argoti et 
al. 2005). However, there are other proposed mechanisms in the literature that 
suggest that the parent compound was the cause of hepatotoxicity in patients taking 
nefazodone. Indeed, Dykens et al, 2008 (Dykens et al. 2008) demonstrated that 
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nefazodone could elicit its toxicity through inhibition of complex I of the oxidative 
phosphorylation chain causing a collapse of the mitochondrial membrane potential 
and Kostrubsky et al, 2006 (Kostrubsky et al. 2006) have shown that nefazodone 
inhibits its own excretion into the bile through the bile salt export pump (BSEP) 
causing an accumulation, not only of nefazodone, but also of toxic bile salts in the 
liver. In neither case did the metabolism of the compound make it more toxic. 
Buspirone, an anti-anxiety drug introduced in the 1980s, is also metabolised by 
CYP450 3A4 (Zhu et al. 2005) to several hydroxy metabolites and like nefazodone 
has the potential to undergo para-hydroxylation that can lead to the formation of a 
quinone-imine reactive metabolite species. However, unlike nefazodone, buspirone 
has not been associated with any reported cases of organ-directed toxicity and 
studies have not identified a buspirone reactive metabolite (Kalgutkar et al. 2005b). 
Despite this both nefazodone and buspirone have been reported to irreversibly bind 
to human hepatocytes at similar levels (Bauman et al. 2009, Obach et al. 2008) and 
the result of this study suggested that it is the differing daily dose, the recommended 
nefazodone dose (up to 600mg a day) being 10 times the daily dose of buspirone (up 
to 60mg a day), that results in their differences in toxicity. 
Due to the conflicting arguments in the literature about the production of reactive 
metabolites and their link to toxicity, the irreversible binding and metabolism of 
nefazodone was investigated to try and provide a definitive link between reactive 
metabolite formation and the hepatotoxicity of nefazodone.  
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Figure 3.1 Chemical structures of nefazodone and buspirone. * Indicates the position of 
the radiolabel. 
3.2 MATERIALS AND METHODS 
 
3.2.1 Materials  
 
Nefazodone was kindly purchased by Pfizer from Bosche Scientific (New Jersey, 
USA). Buspirone and methapyrilene were purchased from Sigma Aldrich (Poole, 
UK). [14C] radiolabels were provided by Pfizer. Collagenase was purchased from 
Roche (UK). CellTiter-Glo® Luminescent Cell Viability (ATP) Assay was 
purchased from Promega (UK). All other reagents were purchased from Sigma-
Aldrich (Poole, UK) unless otherwise stated. Solvents were purchased from Fischer 
Scientific and were all at least HPLC grade. Animals were purchased from Charles 
River (UK). 
3.2.2 Rat Hepatocyte isolations 
 
Rat hepatocytes were isolated as previously described by Williams et al 
(2007)(Williams et al. 2007). Male Wistar rats were anaesthetised using sodium 
pentobarbital (60mg/ml 1µl/g i.p). The hepatic portal vein was cannulated and the 
liver was perfused for 9 mins at a constant flow rate of 40 ml/min with a wash buffer 
O
N N
N
O
N
ClN
N
N
N N
N
O
O
*
*
Nefazodone
Buspirone
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containing Hanks’ balanced salt solution, 5.8mM HEPES and 4.5mM NaHCO3. The 
wash step was followed by a collagenase perfusion using wash buffer with 5mM 
CaCl2, 0.5mg/ml Collagenase A and 0.072 mg/ml trypsin inhibitor until the liver 
was visually judged to be digested. All wash and digestion solutions were kept at 
37˚C throughout the perfusion. The liver was then excised and the liver capsule 
removed to release the cells. The cells were then re-suspended in 50ml of wash 
buffer supplemented with DNase I (0.1mg/ml) and filtered through 125µm nylon 
mesh. The cell suspensions were then left to settle for 10 min on ice before the 
supernatant was removed. The cells were re-suspended in wash-DNase I and 
centrifuged at 50g for 2 mins. This was repeated twice more with wash buffer alone. 
The cells were re-suspended in incubation buffer (wash buffer with 1mM 
MgSO4.7H2O). Hepatocyte viability was assessed by trypan blue exclusion and only 
used when viability was greater than 80%.  
3.2.3 Rat hepatocyte incubations 
Experimental hepatocyte incubations contained a total volume of 6ml with a 
concentration of 2x106cells/ml. For dose response studies there was a final 
concentration range of 0-500µM nefazodone or buspirone. For studies investigating 
the effect of 1-aminobenzotriazole (ABT) hepatocytes were incubated with 0-200µM 
final concentration of nefazodone or buspirone following pre-incubation for 30 
minutes with ABT (1mM). Hepatocytes were incubated for 6 hours at 37ºC, under 
normal atmospheric conditions and 180rpm. Viability was assessed using trypan blue 
exclusion and ATP assay. Samples (1ml) were also taken to determine cellular GSH 
content. Remaining hepatocyte suspension was quenched with an equal volume of 
ice-cold methanol for metabolism. 
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3.2.4 Irreversible binding in rat hepatocytes  
Hepatocytes were incubated (as above) with 200µM cold drug and 0.1µCi [14C] 
nefazodone or buspirone for 0, 0.5, 1, 2, 4 or 6 hours and cells were then processed 
as above. Remaining hepatocyte suspension was used for analysis of irreversible 
binding. 
3.2.5 Human hepatocyte isolations  
Liver tissue from patients that had undergone liver resection was washed with 1-2L 
of 1x HEPES buffer at 50-75ml/min with no re-circulation. The liver was then 
perfused with re-circulated collagenase perfusion for approximately 20 minutes until 
the liver was soft and hepatocytes could be easily removed from the liver. The 
hepatocytes were then filtered through a 125µM nylon mesh. The cells were then 
washed 3 times in ice-cold William’s E media before being transferred to incubation 
buffer and washed twice more. Cells were used for incubations if viability, as 
assessed by trypan blue, was greater than 90%. 
3.2.6 Human hepatocyte incubations  
Human hepatocytes were incubated with 0-200µM nefazodone for 6 hours in 
incubation buffer. After 6 hours viability, GSH content and metabolism was 
assessed. Cells were only used at 6 hours if control viability was greater than 60%. 
For ABT incubations, hepatocytes were pre-incubated at 37°C for 30mins, before 
addition of either 100 or 200µM nefazodone. 
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Patient 
number  
Sex  Age  Medications (excluding chemotherapy)  Chemotherapy  
3  M  73 Tamsulosin/heparin  Capecitabine, 
oxaliplatin, 
irinotecan, 
cetuximab  
4  F  51 -  -  
6  M  73 Atenolol  Capecitabine, 
oxaliplatin  
9  M  53  Valproate/simvastatin/salmeterol/salbutamol  -  
Table 3.1. Donor information for human hepatocyte incubations. Human hepatocyte 
donors were all undergoing liver resection for hepatic cancer. Healthy liver tissue removed 
during resections was used to isolate hepatocytes. 
 
3.2.7 Buspirone LC-MS method 
 
LC-MS/MS analysis was performed on an API 2000. The LC system consisted of an 
Agilent Eclipse XDB C18 column (4.6x150mm, 5µ). The aqueous phase was 15mM 
ammonium formate (A). The organic solvent (B) was acetonitrile (ACN). A gradient 
separation was used starting initially with 10% B rising to 30% B over 35 minutes 
and held at 30% for 5 minutes. 25µl of sample was injected onto the column. The 
ion-spray was operated at +5000 v and a temperature of 400˚C. MS/MS was used to 
extract ions according to m/z found in Kerns et al, 1997. 
3.2.8 Nefazodone LC-MS method  
The LC system consisted Phenomenex Luna phenyl-hexyl column (4.6x100mm, 5µ) 
with a Perkin Elmer pump and autosampler attached to an API2000 mass 
spectrometer. The mobile phase consisted of 15mM ammonium formate (A) and 
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ACN (B). A gradient separation was run beginning at 5% B and rising to 70% B 
over 25 minutes, the gradient returned to 5% B over the next minute and then ran at 
5% B until 30 minutes. 
3.2.9 Cellular GSH determination  
 
Hepatocytes were spun at 1000rpm for 2 minutes and the supernatant was removed 
and discarded. The pellet was lysed with 10mM HCl and vortexed. A fifth was 
removed to be kept for protein determination and replaced with 6.5% 5’-
sulfosalicyclic acid (SSA) to precipitate the protein. After 10 minutes on ice the 
samples were spun for 5 minutes at 14,000rpm and the supernatant kept for analysis. 
The GSH content was measured as according to Vandeputte et al (Vandeputte et al. 
1994) and was measured at a wavelength of 412nm. Standards ranged from 0-40 
nmol/ml. GSH content was normalised to protein content of the cell. 
3.2.10 Protein determination  
 
Protein content was determined using a Lowry assay (LOWRY et al. 1951) as in 
chapter 2. 
3.2.11 Cultured hepatocyte isolation 
 
Hepatocytes for cell culture were isolated from male Han Wistar rats weighing 
between 200-350g. Rats were anaesthetised using isoflurane in an induction chamber 
before being moved to a nose cone for maintenance. A V-shaped incision was made 
in the abdomen and the guts moved to one-side. A loose tie was placed around the 
portal vein before the diaphragm was cut. A cannula was placed in the hepatic portal 
vein and tied in place before the removal of the heart to allow free loss of perfusion 
buffers. The liver was perfused with HBSS (-CaCl2/-MgCl2) at a flow rate of 
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25ml/min until the liver was completely blanched and free of blood. The liver was 
then perfused with digestion media (HBSS with 5mM CaCl2 and collagenase type II) 
until visually well digested, before being removed and placed in collection media 
(HBSS with 5mM CaCl2 and 10,000U DNase). Hepatocytes were teased from the 
liver using a scapel blade into media containing DNase and filtered through a 100µ 
mesh. The hepatocytes were centrifuged a 30g for 5 minutes before being washed 
and spun again. The hepatocytes were then centrifuged at 60g for 10 minutes in a 
percoll gradient to separate the alive and dead cells. The cells were washed twice 
more in attachment media before being counted using a Guava machine. The cells 
were seeded at a density of 0.25x106 cells/ml into collagen-coated 96-well plates in 
attachment media and placed in the incubator at 37°C/5% CO2. After a minimum of 
2 hours the attachment media was removed and replaced with basal media (no FBS). 
The cells were then left to settle before dosing. 
3.2.12 Cellomics analysis 
 
Hepatocytes were dosed with a final concentration of 0-100μM nefazodone or 
buspirone dissolved in 0.1% DMSO for 24, 48 or 72 hours. At each time point the 
media was removed and replaced with basal media containing Hoechst 33342 (1 in 
10000), TMRM (1 in 200) and TO-PRO 3 iodide (1 in 1000). Plates were then 
returned to the incubator for 20 minutes to allow uptake of the dyes. The plates were 
then read using Cellomics technology.  
3.2.13 Animal Work 
All animal work was carried out according to local ethics policies and in accordance 
with home office regulation. 
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3.2.14 Human Ethics Approval 
 
All work with human samples was carried out in accordance with local ethics 
policies. 
3.2.15 Statistical analysis 
Statistical analysis was undertaken using Stats Direct software. Data was tested for 
normality using a Shapiro-Wilks test and either a Student’s T test (parametric) or 
Mann-Whitney U test (non-parametric) was used to make comparisons between data 
sets. An ANOVA (Dunnett’s comparison to control) was used to determine 
significance to control values. 
3.3 RESULTS 
 
3.3.1 Metabolism of buspirone in freshly isolated rat hepatocytes 
The metabolism of 100μM and 200μM buspirone was investigated in rat hepatocytes 
in suspension. Identification of the metabolites of buspirone were based upon the 
previous work of Kerns et al (Kerns et al. 1997), who identified several buspirone 
metabolites in rat bile and urine and rat liver S9 preparations. Buspirone (m/z 386) 
exhibited extensive turn over in rat hepatocytes to several phase I and II metabolites 
through hydroxylation, N-dealkylation, catechol O-methylation and glucuronidation. 
Several [O] buspirone, m/z 402 (figure 3.3) and [2O] buspirone, m/z 418 were 
identified. The fragment ions of these metabolites indicated that hydroxylation 
occurred on both the azaspirone and pyrimidinyl moieties, a shift of m/z 123 to m/z 
139 indicating hydroxylation on the azaspirone structure and a shift of m/z 122 to 
m/z 138 indicating hydroxylation on the pyrimidine structure. Buspirone was also 
turned over to several [2O, OCH3] metabolites (m/z 448), thought to be formed 
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through the sequential hydroxylation and O-methylation of the buspirone molecule. 
Buspirone also underwent N-dealkylation reactions to 1-pyrimidinyl-piperazine (m/z 
165), despyrimidinyl buspirone (m/z 308) and despyrimidinyl piperazine buspirone 
(m/z 254). Phase II reactions consisted mainly of glucuronidation reactions (fig 3.4), 
confirmed by neutral loss of 176 amu. [O] buspirone glucuronide (m/z 578) , [2O] 
buspirone glucuronide (m/z 594), [O, OCH3] buspirone glucuronide (m/z 608) and 
[2O, OCH3] buspirone glucuronide (m/z 624) were all identified and corresponded 
with the phase I metabolites present. Despite hydroxylation of the pyrimidinyl 
moiety and therefore the possibility of para-hydroxy buspirone formation, no GSH 
conjugates of buspirone were identified. The AUC values for each metabolite can be 
found in appendix III. 
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Name  m/z  Retention time  
1-pyrimidinylpiperazine  165  6.36 
[2O] buspirone glucuronide  594  14.8 
[2O, OCH3] buspirone glucuronide  624  16.5 
[2O] buspirone glucuronide  594  17.1 
[2O] buspirone  418  17.5 
[2O] buspirone  418  18 
[2O] buspirone  418  18.5 
[2O, OCH3] buspirone glucuronide  624  18.8 
[2O] buspirone  418  18.9 
[2O] buspirone glucuronide  594  19.6 
[2O, OCH3] buspirone  448  19.8 
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[2O] buspirone  418  20.2 
[O] buspirone  402  20.8 
[2O, OCH3] buspirone  448  20.9 
[2O, OCH3] buspirone glucuronide  624  21.1 
[O] buspirone  402  21.2 
[2O] buspirone  418  22.6 
[O] buspirone glucuronide  578  22.9 
[O] buspirone  402  23.7 
[O, OCH3] buspirone glucuronide  608  24.1 
Despyrimidinyl buspirone  308  25 
[2O] buspirone  418  25 
[O, OCH3] buspirone  432  25.3 
[O] buspirone  402  26.1 
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[O] buspirone  402  27.5 
Despyrimidinylpiperazine  254  27.9 
Buspirone  386  28.6 
Table 3.2. Buspirone metabolites identified from rat hepatocyte incubations. 
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Figure 3.3 Product ion scan m/z 402 and fragment ions of [O] buspirone. (A) TIC for 
product ion scan of m/z 402. (B) Fragment ions of [O] buspirone substituted on the 
azaspirone moiety. Fragment ions related to the m/z 122 (unsubstituted pyrimidine) and m/z 
139 (hydroxylated azaspirone moiety) are highlighted in purple. (C) Fragment ions of [O] 
buspirone substituted on the pyrimidine moiety. The fragment ion m/z 138 (hydroxylated 
pyrimidine) is highlighted in green.  
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Figure 3.4. Glucuronide metabolites of buspirone in primary rat hepatocytes. (A) 
Neutral loss scans of 176u for identification of glucuronide metabolites. (B) Identified 
glucuronide metabolites and their fragment ions.  
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3.3.2 The metabolism of nefazodone in freshly isolated rat hepatocytes 
 
In rat hepatocytes the metabolic profile of nefazodone was concentration dependent, 
with a different metabolism profile appearing with 100μM and 200μM incubations 
(figure 3.6). The major pathways of metabolism appear to be similar to buspirone 
and consist mainly of hydroxylation, N-dealkylation and glucuronidation. Hydroxy 
metabolites of nefazodone are particularly important to the theory that nefazodone 
causes toxicity through reactive metabolite formation, particularly those with a 
fragment ion of m/z 274 indicating an unsubstituted phenoxyethyl-triazolone-propyl 
moiety. A lack of hydroxylation of the phenoxyethyl-triazolone-propyl fraction (m/z 
274) indicates that hydroxylation has probably occurred in the 
chlorophenylpiperazine ring and therefore hydroxylated metabolites with a fragment 
ion at m/z 274 may be para-hydroxylated and have the potential to form a reactive 
quinine-imine species. At 100μM nefazodone only one [O] nefazodone peak was 
prominent (peak 9) which appeared to consist of a mixture of at least two co-eluting 
[O] nefazodone metabolites, which yielded both the m/z 274 and m/z 290. In the 
200μM incubations a second [O] nefazodone peak was also present that consisted 
only of the m/z 290 fragment indicating hydroxylation on the phenoxyethyl-
triazolone-propyl moiety and, therefore, this metabolite is unlikely to undergo 
bioactivation. One of the [O] nefazodone metabolites underwent a sulphation 
reaction to yield an O-sulphonate metabolite (m/z 566) which gave a prominent peak 
in the 100μM sample (peak 7) but was less abundant at 200μM. The O-sulphonate 
yielded a fragment ion of m/z 274 indicating the presence of the unsubstituted 
phenoxyethyl-triazolone-propyl fragment. Two of the [O] nefazodone metabolites 
also underwent glucuronidation, forming peaks 3 and 4 (m/z 662). There were also 
two [2O] nefazodone metabolites which were prominent in both 100μM and 200μM 
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incubations (peaks 5 and 6). These both underwent glucuronidation to [M+H+] m/z 
678, although glucuronidation appeared to be less in the 200μM incubations. Several 
carbonyl metabolites were also present. Phenoxy-triazolone carboxylic acid (peak 8) 
was a prominent peak in both 100μM and 200μM incubations but the triazolone 
ethylcarbonyl derivative (peak 12), a product of sequential hydroxylation and 
dehydrogenation was only found in the 200μM incubation. The di-oxygenated ([O, 
=O]) metabolite (m/z 500, peak 10) co-eluted with other metabolites but clearly 
displayed the phenoxyethyl-ketotriazolone-propyl fragment (m/z 288) and could be 
confirmed as a metabolite due to the characteristic double peak of +35Cl and +37Cl 
seen with chlorinated compounds. A deschlorophenyl metabolite (m/z 360) and 3-
chlorophenylpiperazine (m/z 197) were also identified in both concentrations of 
hepatocyte samples, co-eluting with other metabolites in peaks 1 and 2, respectively. 
3-chlorophenylpiperazine is also thought to be hydroxylated to a para-hydroxy 
metabolite, however [O] 3-chlorophenylpiperazine was not identified in any of the 
rat hepatocyte samples. Whether this was due to the absence of the metabolite or 
because it was too polar to be detected was not determined. Unlike in RLM 
incubations (chapter 2) no GSH conjugates of nefazodone could be identified in rat 
hepatocyte isolations. There is a possibility that this is due to the high turnover of 
nefazodone to glucuronides and sulphonates in hepatocytes and GSH conjugates are 
not formed in the same manner as in RLM incubations where GSH is the only phase 
II reaction available. Table 3.3 details the metabolites identified in rat hepatocytes 
dosed with 200µM nefazodone and a metabolic scheme in figure 3.7 and appendix 
IV contains the AUC of each nefazodone metabolite. 
  
96 
 
Nefazodone and buspirone: reactive metabolite formation and toxicity to hepatocytes 
 
Figure 3.6. Representation of the total ion current of (A) 100μM and (B) 200μM 
nefazodone in freshly isolated rat hepatocytes.  
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Number  Name  m/z  Retention time 
(mins)  
1  Deschlorophenyl nefazodone  360  13.18  
2  [2O] nefazodone glucuronide  678  13.31  
2  [2O] nefazodone glucuronide  678  13.67  
3  Chlorophenylpiperazine  197  13.66  
4  [O] nefazodone glucuronide  662  14.60  
4  [O] nefazodone glucuronide  662  14.61  
5  [2O] nefazodone  502  15.52  
5  [2O] nefazodone  502  15.84  
6  Nefazodone O-sulphonate  566  16.34  
7  Phenoxyethyltriazolone propanoate  306  16.61  
8  [O] nefazodone  486  16.68  
9  [O, =O] nefazodone  500  17.56  
8  [O] nefazodone  486  17.71  
Nefazodone  Nefazodone  470  19.24  
10  [=O] nefazodone  484  20.27  
 
Table 3.3. Metabolites of nefazodone in rat hepatocytes 
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3.3.3 The metabolism of nefazodone in freshly isolated human 
hepatocytes 
 
The metabolism of nefazodone in human hepatocytes was extensive and as in the rat 
the metabolite profile was concentration dependent. The retention times of all the 
metabolites are summarised in table 3.4 and the AUC of each metabolite can be 
found in appendix V. Several differences existed between the turnover of nefazodone 
in rat and human hepatocytes (figure 3.8). The major difference between the 
incubations at 100μM nefazodone was a difference in the production of mono-
oxygenated metabolites (m/z 486). Whereas rat hepatocytes produced 1 major and 3 
minor metabolites corresponding to an m/z 486, human hepatocytes produced 3 
major and 1 minor [O] nefazodone metabolite. This is also in contrast to HLMs 
where 3 [O] nefazodone metabolites were detected (chapter 2). The [O] nefazodone 
metabolites can be seen in figure 3.7. The most polar of the four [O] metabolites (I 
and II) produced a fragment ion with m/z 274 and the least polar [O] metabolites (III 
and IV) had the fragment ion m/z 290. The phase II metabolites of [O] nefazodone 
were much less prominent than in rat hepatocytes although the O-sulphonate (peak 
11) and the two glucuronides (peaks labelled 7) were still present. Five di-
oxygenated metabolites were identified consisting of 2 [2O] nefazodone and 3 [O, 
=O] nefazodone metabolites. There was also a glucuronide conjugate of [2O] 
nefazodone detectable. The 3 [O, =O] nefazodone metabolites are represented in 
figure 3.9. Metabolite I exhibited a fragment ion with an m/z of 288 representing 
phenoxyethyl-ketopropyl triazolone. Metabolite II only had a fragment ion present at 
m/z 274 indicating unchanged phenoxyethyl-propyltriazolone, whilst metabolite III 
had a fragment ion at m/z 304 indicating the presence of phenoxyethyl-
oxyketopropyltriazolone following both hydroxylation and carbonyl formation on 
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the phenoxyethyl-propyltriazolone moiety. Unlike in rat hepatocytes a [3O] 
nefazodone metabolite was detected (m/z 518). The [3O] nefazodone metabolite had 
a fragment ion of m/z 290 indicating that only one of the hydroxylation reactions 
was present on the phenoxyethyl-propyl triazolone structure, but it could not be 
identified where the other hydroxylation reactions occurred based on the 
fragmentation pattern. As in rat hepatocyte isolations no GSH conjugates were 
identified in the human hepatocyte incubations. 
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Figure 3.8. Total ion current of nefazodone and metabolites in freshly isolated human 
hepatocytes (from patient 3). 
 
Figure 3.9. [O] nefazodone metabolites identified in human hepatocyte samples. Four 
[O] nefazodone metabolites were identified in patient samples. The most polar metabolites (I 
and II) produced the fragment ion m/z 274 indicating an unsubstituted phenoxyethyl-
triazolone-propyl fragment, whilst the less polar metabolites (III and IV) displayed the 
fragment ion m/z 290 indicating oxidation of the phenoxyethyl-triazolone-propyl moiety. 
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Figure 3.10. [=O,O] nefazodone metabolites identified in human hepatocyte samples. 3 
[=O, O] nefazodone metabolites were identified in human hepatocyte samples. I 
demonstrated a fragment ion of m/z 288, II a fragment ion of m/z 274 and III a fragment ion 
of m/z 304. (A) Total ion current of nefazodone in human hepatocytes. (B) m/z 500 +35Cl 
form of [=O, O] nefazodone. (C) m/z 502 +37Cl form of [=O,O] nefazodone highlighted. 
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Number  Name  m/z  Retention time 
(mins)  
H1  3-chlorohydroxyphenylpiperazine  213  4.25  
H2  Deschloro [O] phenyl nefazodone  376  8.43  
2  [2O] nefazodone glucuronide  678  9.08  
7  Phenoxyethyltriazolone propanoate  306  9.34  
3  Chlorophenylpiperazine  197  9.60  
1  Deschlorophenyl nefazodone  360  10.09  
4  [O] nefazodone glucuronide  662  10.58  
H3  Deschlorophenyl [=O] nefazodone  374  10.69  
4  [O] nefazodone glucuronide  662  11.18  
H4  [3O] nefazodone  518  11.30  
H5  Phenoxyethyltriazolone n-propanol  292  12.02  
5  [2O] nefazodone  502  12.62  
6  Nefazodone O-sulphonate  566  12.62  
H6  [O] deschloronefazodone  451  12.78  
H7  Desethylketo nefazodone  458  13.54  
5  [2O] nefazodone  502  14.01  
8  [O] nefazodone  486  14.68  
8  [O] nefazodone  486  15.65  
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8  [O] nefazodone  486  16.17  
9  [O, =O] nefazodone  500  16.23  
8  [O] nefazodone  486  17.00  
9  [O, =O] nefazodone  500  17.73  
9  [O, =O nefazodone]  500  19.07  
Nefazodone  Nefazodone  470  19.58  
10  [=O] nefazodone  484  22.36  
Table 3.4. Nefazodone metabolites identified in human hepatocyte 
isolations. 
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3.3.4 Effect of ABT on nefazodone metabolism in human hepatocytes 
 
The pre-incubation of the hepatocytes with ABT effectively inhibited turnover of 
nefazodone, the major exception to this was [O] nefazodone I, which appears not be 
inhibited by ABT and was deemed not be a CYP450 3A4 mediated reaction, being 
catalysed by either an ABT insensitive CYP450 or another phase I metabolising 
enzyme. 
3.3.5 Effect of nefazodone and buspirone on cellular toxicity and GSH 
levels in rat hepatocytes 
 
A reduction in cellular GSH concentration can indicate the depletion of GSH through 
conjugation to reactive metabolites. If the cells are thought to be dying through 
depletion of GSH and exposure to covalent protein modification the cells exhibit a 
significant decrease in cellular GSH concentration before cell death occurs, however, 
cell death can also be the cause of GSH depletion as GSH leaks from dead cells. The 
trend in viability and GSH depletion for nefazodone and buspirone can be seen in 
figure 3.12. Both nefazodone and buspirone significantly deplete GSH, however, the 
trend in GSH depletion is very different. Nefazodone exhibits significant cell toxicity 
at 200μM after 6 hours, however, buspirone only begins to exhibit significant 
toxicity after reaching concentrations of 1mM, much higher than the 0.0045μM 
serum Cmax reached after a single dose of 20mg buspirone. Nefazodone did 
significantly deplete GSH but the depletion of GSH followed toxicity very closely 
and as a result of this trend it is likely that the GSH depletion seen with nefazodone 
is likely to be a consequence and not a cause of cell death. Unexpectedly, buspirone 
also significantly depleted GSH; however, this occurred in the absence of 
107 
 
Nefazodone and buspirone: reactive metabolite formation and toxicity to hepatocytes 
cytotoxicity. This indicates that GSH depletion could be a potential mechanism for 
buspirone mediated cell death at high buspirone doses. 
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Figure 3.12. The effect of nefazodone and buspirone on cell viability and cellular GSH 
levels. Hepatocytes were dosed with 0-200μM nefazodone or buspirone for 6 hours and the 
viability was assessed for nefazodone using trypan blue exclusion (A) and cellular ATP 
content (B) and compared to cellular GSH levels. Buspirone (C) was assessed using trypan 
blue and compared to GSH. Both viability (●) and GSH levels (○) are expressed as % 
control values. Values are mean±SEM from 4 independent isolations. 
***P<0.001determined using ANOVA (Dunnet’s multiple comparison to control). 
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3.3.6 The effect of ABT on nefazodone cytotoxicity in freshly isolated rat 
hepatocytes 
 
Incubations of nefazodone in the presence and absence of a 30 minute pre-incubation 
with ABT (1mM) demonstrated a decrease in cell viability determined by both 
trypan blue exclusion and cellular ATP content (figure 3.13). Cell viability was not 
significantly different in control incubations in the presence and absence of ABT, 
99.5±2.33% control and 94.5±10.5% control for trypan blue exclusion and ATP 
content respectively. A significant decrease in cell viability was observed when 
hepatocytes were pre-incubated with ABT with both 20μM (98.75±2.72% control vs 
88.25±1.55% control), 50μM (94.5±1.19% control vs 79.75±2.56% control) and 
100μM (89.5±4.59% control vs 41±3.84% control) using trypan blue exclusion and 
50μM (107.25±9.8% control vs 74.25±4.66% control) and 100μM (83.75±3.7% 
control vs 36.0±13.40% control) using assessment of ATP content. 
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Figure 3.13. The effect of ABT on the toxicity of nefazodone in freshly isolated 
hepatocytes. Freshly isolated hepatocytes were incubated with 0-200μM nefazodone over 6 
hours in the absence (●) and presence (○) of 1mM ABT and viability was determined using 
trypan blue exclusion (A) and cellular ATP content (B). Values are mean ± SEM from 4 
independent isolations. *P<0.05 determined using a Mann Whitney U test.  
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3.3.7 Irreversible binding in freshly isolated rat hepatocytes  
 
In freshly isolated rat hepatocytes both nefazodone and buspirone exhibited 
significant irreversible binding at 6 hours. Despite significant irreversible binding of 
buspirone at 6 hours there was no significant decrease in cell viability which was 
99.33±1.33 % control viability (figure 3.14). In contrast nefazodone exhibited 
significant irreversible binding (117.54±15.32 pmol equiv./mg protein) and a 
significant decrease in cell viability (19.25±18.26 % control viability) at 6 hours 
(figure 3.11). Surprisingly when a comparison between the irreversible binding of 
nefazodone and buspirone was carried out there was no significant difference 
between the irreversible binding at any time point, despite a significant difference in 
cytotoxicity elicited by the two drugs from 2 hours onwards (figure 3.15). 
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Figure 3.14. Comparison of the irreversible binding and cell viability in freshly isolated 
rat hepatocytes treated with nefazodone and buspirone. Freshly isolated rat hepatocytes 
were incubated with 200μM nefazodone (A) or buspirone (B) and 0.1μCi of the 
corresponding [14C] labelled compound for 0-6 hours. Viability was determined using trypan 
blue exclusion is expressed as % control values. Irreversible binding is expressed as pmol 
equiv/mg protein. Values are mean±SEM from 4 independent isolations. Significance to 
control values was determined using an ANOVA (Dunnett’s multiple comparison to 
control). *P<0.05, **P<0.01, ***P<0.001.  
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Figure 3.15. Comparison of irreversible binding and cell viability of freshly isolated rat 
hepatocytes treated with nefazodone and buspirone. Freshly isolated rat hepatocytes were 
incubated with 200μM nefazodone or buspirone and 0.1μCi of the corresponding [14C] 
radiolabelled compound for 0-6 hours. Irreversible binding (A) is expressed as pmol 
equiv./mg protein. Cell viability (B) was determined by trypan blue exclusion and is 
expressed as % control values. Values are mean±SEM and are from 4 independent 
isolations. Significance between nefazodone and buspirone was determined using an 
unpaired t-test. *P<0.05 **P<0.01. 
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3.3.8 The effect of ABT on toxicity and irreversible binding of nefazodone 
in freshly isolated rat hepatocytes  
 
To determine whether CYP450s are involved in the metabolic activation and 
irreversible binding of nefazodone, hepatocytes were pre-incubated with ABT 
(1mM) for 30 minutes. The pre-incubation with ABT significantly reduced the 
irreversible binding of nefazodone from 117.54±15.32 pmol equiv./mg protein to 
49.34±4.64 pmol equiv./mg protein. However, the viability of the hepatocytes also 
decreased (figure 3.16) indicating that the irreversible binding may not be the cause 
of nefazodone toxicity in rat hepatocytes. Use of the positive control, methapyrilene, 
demonstrated that pre-incubation with ABT could prevent metabolic activation and 
hence cytotoxicity of compounds where a reactive metabolite is a known cause of 
toxicity (Graham et al. 2008) (figure 3.17).  
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 Figure 3.16. Effect of ABT on cytotoxicity and irreversible binding in freshly isolated 
rat hepatocytes. Freshly isolated rat hepatocytes were incubated with 200μM nefazodone 
and 0.1μCi [14C] nefazodone for 0-6 hours in the presence (○) and absence (●) of 1mM 
ABT. Viability was determined via trypan blue exclusion (A) and ATP content (B) and is 
expressed as % control. Irreversible binding (C) is expressed as pmol equiv/mg protein. 
Values are mean±SEM from 4 independent isolations. *P<0.05 nefazodone vs nefazodone + 
ABT determined using a Mann Whitney U test. 
Time (hours)
0 1 2 3 4 5 6 7
V
iability
(%
control)
0
20
40
60
80
100
120
*
* *
*
*
Time (hours)
0 1 2 3 4 5 6 7
Irreversible
binding
(pm
olequiv./m
g
protein)
0
20
40
60
80
100
120
140
*
Time (hours)
0 1 2 3 4 5 6 7
Viability
(%
control)
0
20
40
60
80
100
120
*
*
A
B
C
116 
 
Nefazodone and buspirone: reactive metabolite formation and toxicity to hepatocytes 
 
Figure 3.17. Effect of ABT on cells treated with methapyrilene. Freshly isolated rat 
hepatocytes were incubated with 200µM methapyrilene for 6 hours and viability was 
assessed by trypan blue exclusion. **P<0.01. MP, 200µM methapyrilene; MP+ABT, 200µM 
methapyrilene + 1mM ABT. 
 
3.3.9 Cytotoxicity of nefazodone and buspirone in cultured rat 
hepatocytes using Cellomics technology 
 
Cultured hepatocytes from Han Wistar rats were incubated with nefazodone and 
buspirone (0-100μM) for 24-72 hours. Figure 3.18. shows representative images of 
hepatocytes dosed with 0.1% DMSO, 100µM nefazodone and 100µM buspirone at 
24hours. The hepatocytes were stained by Hoechst 33342 for nuclei and nuclear 
condensation, TMRM for mitochondrial membrane potential and TO-PRO-3 iodide 
for cell membrane integrity. The images show that the hepatocytes treated with 0.1% 
DMSO vehicle exhibit round normal shaped morphology, with a healthy 
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mitochondrial membrane potential and living cells with membrane integrity. Cells 
treated with buspirone produced similar imaging results as the 0.1% DMSO vehicle. 
On the other hand hepatocytes treated with 100µM nefazodone displayed nuclear 
condensation, dissipation of the mitochondrial membrane potential and a lack of cell 
membrane integrity. The hepatocyte images were analysed using ArrayScan software 
and the mean object intensity was used to assess Hoechst 33342, mean target 
intensity for TMRM and mean total target intensity for TO-PRO-3 iodide. Using 
Hoechst 33342 to assess nuclear condensation nefazodone (100μM) demonstrated  a 
significantly increased fluorescence signal compared to 0.1% DMSO vehicle control 
(24hrs, 300.85±21.15 % control; 48hrs, 413.84±21.15 % control; 72hrs, 365.79± 8.0 
% control), whereas buspirone did not exhibit significantly increased fluorescence at 
any dose or time point. Cells stained with TO-PRO-3 iodide also indicated 
significance at all time points with nefazodone (100μM; 24hrs, 411.08±67.25 % 
control; 48hrs, 425.61±70.68 % control; 72hrs, 493.97±152.87 % control) indicating 
cell permeability, but not with buspirone. Significantly decreased TMRM 
fluorescence, indicated mitochondrial dysfunction in cells treated with nefazodone 
(100μM; 24hrs, 44.20±4.68 % control; 48hrs, 47.43±5.02 % control; 72hrs, 
57.75±12.85 % control) (figure 3.19) but not with buspirone when compared to 0.1% 
DMSO controls (figure 3.20). 
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Figure 3.18. Images of cultured hepatocytes treated with 100μM nefazodone or 
buspirone after 24 hours. Representative images of hepatocytes treated for 24 hours with 
0.1% DMSO (left column), 100µM nefazodone (middle column) and 100µM buspirone 
(right column). They were stained with Hoechst 33342 for nuclei (1st row), TMRM or 
mitochondrial membrane potential (2nd row) and TO-PRO-3 iodide to indicate membrane 
permeability. 1 indicates staining of hepatocytes with Hoechst 33342 with normal 
morphology. 2 demonstrates hepatocytes with a condensed nucleus following cell death 
stained with Hoechst 33342. 3 shows hepatocytes with normal mitochondrial membrane 
potential stained with TMRM, which cannot be seen in nefazodone treated cells. 4 shows 
cells with TO-PRO-3 iodide staining indicating disruption to the cell membrane and 
therefore TO-PRO-3 iodide staining of nuclear acids, which is not demonstrated in control 
(0.1% DMSO) treated cells. 
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Figure 3.19. The cytotoxicity of nefazodone in cultured rat hepatocytes assessed using 
Cellomics technology. Hepatocytes from male Han Wistar rats were cultured with 0-100μM 
nefazodone for 24, 48 and 72 hours and assessed using (A) Hoechst 33324, (B) TMRM and 
(C) TO-PRO-3 iodide and expressed as % of control values. Data is from 3 independent 
isolations and is expressed as mean ± SEM.   
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Figure 3.20. The cytotoxicity of buspirone in cultured rat hepatocytes assessed using 
Cellomics technology. Hepatocytes from male Han Wistar rats were cultured with 0-100μM 
for 24, 48 and 72 hours and assessed using (A) Hoechst 33324, (B) TMRM and (C) TO-
PRO-3 iodide and expressed as % of control values. Data is from 3 independent isolations 
and is expressed as mean ± SEM.   
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3.3.10 Cytotoxicity of nefazodone in freshly isolated human hepatocytes 
 
The toxicity of nefazodone in human hepatocytes was evaluated using a dose 
response of nefazodone (0-200μM) over 6 hours in suspension cells. There was 
significant toxicity in cells dosed with 100 and 200μM nefazodone (figure 3.21), 
using both trypan blue exclusion and ATP assay. Significant GSH depletion 
occurred, however, the GSH concentration in the hepatocytes was much lower than 
expected, possibly due to the age and health of the patients in combination with the 
isolation procedure (figure 3.22.). Despite this, the trend still indicated that GSH 
depletion was not the cause of cell death, the same relationship that is seen in rat 
hepatocytes between GSH and cytotoxicity. 
 
3.3.11 Comparison of nefazodone toxicity in human and rat hepatocytes 
 
The toxicity of nefazodone towards human and rat hepatocytes (figure 3.23) was 
very similar, with near complete cell death at 200μM nefazodone. There was a trend 
towards increased toxicity in human hepatocytes using both trypan blue exclusion 
and to greater extent ATP content, but neither measures of viability were significant.  
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Figure 3.21. Effect of nefazodone on the viability of freshly isolated human hepatocytes. 
Human hepatocytes were treated with 0-200μM nefazodone for 6 hours and viability was 
assessed using trypan blue exclusion (●) and ATP content (○). Data is mean ± SEM from 4 
independent isolations and expressed as % control values. *** P<0.001 determined using 
ANOVA (Dunnet’s comparison to control) 
 
 
Figure 3.22. GSH concentrations in human hepatocytes treated with nefazodone. 
Human hepatocytes were treated with 0-200μM nefazodone and GSH concentration tested. 
Data is mean ± SEM and from 4 independent isolations and expressed as nmol/mg protein. 
*P<0.05 determined using ANOVA (Dunnet’s comparison to control). 
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Figure 3.23. Comparison of the toxicity of nefazodone in freshly isolated rat and 
human hepatocytes. Human and rat hepatocytes were treated with 0-200μM nefazodone 
and viability was assessed with (A) trypan blue exclusion and (B) ATP content. Data is 
mean ± SEM from 4 independent isolations and data is presented as % control viability. 
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3.4 DISCUSSION 
 
The principle aims of the work described in this chapter was to provide a link 
between reactive metabolite formation, irreversible binding and the toxicity elicited 
by nefazodone. In the previous chapter, it was demonstrated that nefazodone could 
produce reactive metabolite species in rat and human liver microsomes. This has 
been previously well documented but a link between the observed bioactivation in 
liver microsomes and toxicity has never been demonstrated. Trying to elucidate the 
mechanisms through which nefazodone induces toxicity may help to inform 
development of safe drugs in the future. 
3.4.1 Metabolism 
3.4.1.1 Reactive metabolite formation and GSH depletion 
It is widely recognised that nefazodone, but not buspirone, can form reactive 
metabolites in human liver microsomes. In accordance with the literature, in chapter 
2 we demonstrated that a hydroxynefazodone glutathione conjugate and a 
dihydroxynefazodone glutathione conjugate could be formed in both human and rat 
liver microsomes. In rat hepatocytes nefazodone and buspirone both demonstrated 
extensive turnover, with hydroxylation, N-dealkylation and glucuronidation 
prevailing as the predominant pathways of drug metabolism. In both rat and human 
hepatocytes hydroxynefazodone was formed with an m/z 274 indicating an 
unsubstituted phenoxyethyl-propyltriazolone fragment making the most likely place 
of hydroxylation the chlorophenylpiperazine moiety. Hydroxylation of the 
chlorophenylpiperazine moiety para to the piperazinyl nitrogen can lead to quinone-
imine formation, which can be detected through the corresponding GSH adduct 
(Baillie, Davis 1993). Unlike in human and rat liver microsomes no GSH conjugates 
could be detected in either rat or human hepatocytes. Despite several sources 
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identifying both p-hydroxy nefazodone and p-dihydroxy nefazodone in rat and 
human liver microsomes (Kalgutkar et al. 2005b, Bauman et al. 2008a, Argoti et al. 
2005). GSH conjugates of nefazodone have never previously been identified in 
hepatocytes, and a study in cultured human hepatocytes also only identified 
glucuronide and sulphate formation from nefazodone metabolites (Kostrubsky et al. 
2006). This may be due to the availability of cytosolic phase II metabolising 
enzymes in hepatocytes that are not present in liver microsomes, resulting in 
glucuronide and sulphate formation rather than the formation of a GSH conjugate. 
There is also the possibility that the nefazodone GSH conjugates are unstable and the 
difference in processing time between liver microsomes and hepatocytes results in 
their degradation, therefore resulting in no detection. As discussed below, buspirone 
produced both significant irreversible binding and GSH depletion in rat hepatocytes, 
however, as with liver microsomes, no GSH conjugates of buspirone were detected. 
Hydroxylation on the pyrimidinyl moiety of some of the hydroxybuspirone 
metabolites was evident from a shift from m/z 122 to 138 in the fragmentation 
pattern indicating the potential for buspirone to undergo bioactivation to a quinone-
imine. In light of the irreversible binding and GSH depletion caused by buspirone it 
is possible that buspirone does produce a GSH adduct that is too unstable to be 
detected using current LC-MS methods. 
GSH is an essential molecule for cellular function and survival. As the most 
abundant reducing molecule in hepatocytes (concentrations of approximately 10mM) 
it is vital for maintaining the redox balance of the cell (Han et al. 2006). It is also a 
major anti-oxidant quenching both endogenous oxidant species and endogenous 
induced oxidative stress, as well as conjugating reactive metabolites produced by 
xenobiotics (DeLeve, Kaplowitz 1991). It can also modulate signalling cascades and 
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the susceptibility of cells to cell death signals, and plays an important role in 
apoptosis (Circu, Aw 2008). It has been shown that quinone-imines, such as NAPQI, 
can attack and irreversibly bind to the cysteinyl residues of cellular proteins. 
Hepatocytes preferentially conjugate the NAPQI formed following metabolism of 
paracetamol to GSH conjugates, however, when a large amount of NAPQI is 
produced this overwhelms the cells leading to depletion of the cellular GSH 
concentration. Once cellular GSH levels become depleted, NAPQI is then free to 
bind to cellular proteins, leading to cell death. 
Despite a lack of GSH conjugates of nefazodone and buspirone both compounds 
significantly depleted GSH compared to control values in rat hepatocyte 
suspensions. The depletion of GSH by nefazodone mirrors the cytotoxicity of 
nefazodone, and there was no significant decrease of GSH concentrations preceding 
hepatocyte cell death. This trend indicates that the depletion of GSH is likely to be 
due to the release of GSH into the surrounding media when the cells die and 
therefore the depletion of GSH by nefazodone is probably a consequence and not a 
cause of cell death.  
Buspirone, however, depleted GSH in a manner that suggests GSH depletion is a 
cause of cell death. Unlike nefazodone, significant depletion of GSH occurred before 
significant cell death. It is a possibility that buspirone does not directly conjugate 
GSH but rather increases ROS formation, and GSH is depleted through the reduction 
of ROS and subsequent oxidation of GSH to GSSG.  
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3.4.1.2. Irreversible binding 
Nefazodone demonstrates time, concentration and NADPH-dependent inactivation 
of CYP450 3A4 in human liver microsomes (Von Moltke et al. 1999a). These 
characteristics are consistent with the observed non-linear pharmacokinetics of 
nefazodone in humans upon dose escalation (Kaul, Shukla & Barbhaiya 1995), as 
well as a wide variety of drug-drug interactions between nefazodone and a number 
of CYP450 3A4 substrates (Abernethy et al. 2001, Helms-Smith, Curtis & Hatton 
1996). It is though that this is mediated by the quinone-imine species that 
nefazodone has been shown to produce in liver microsomes, via irreversible binding 
to CYP450 3A4, leading to auto-inactivation, or to critical cellular proteins leading 
to hepatotoxicity. 
A time course of the irreversible binding and toxicity of nefazodone over 6 hours 
revealed that irreversible binding of GSH increases with a concomitant decrease in 
hepatocyte viability. This mimics the trend seen in other well documented cases, 
where reactive metabolite formation and subsequent irreversible binding of a 
compound leads to cell death. 
To identify that bioactivation through CYP450s and resulting irreversible binding 
was the cause of the cytotoxicity observed in rat hepatocytes, the irreversible binding 
study was repeated following pre-incubation with the non-specific CYP450 inhibitor 
ABT, as well as positive control samples containing methapyrilene. Methapyrilene is 
a known rat hepatotoxin and is bioactivated, in rat hepatocytes, to a reactive 
thiophene metabolite that can bind to macromolecules leading to cell death (Graham 
et al. 2008). Pre-incubation of rat hepatocytes with ABT has been shown to prevent 
the toxicity of methapyrilene to rat hepatocytes. These experiments yielded 
surprising results as although ABT sufficiently prevented both the toxicity of 
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methapyrilene and the irreversible binding of nefazodone as expected, it did not 
prevent the toxicity of nefazodone in hepatocytes. Further experiments in 
hepatocytes revealed that pre-incubating hepatocytes with ABT resulted in a 
significant increase in toxicity at concentrations as low as 20μM nefazodone. This 
trend in increased toxicity was also observed in human hepatocytes, however, due to 
the constraints of retrieving human liver for hepatocyte isolations and the difficulty 
in getting hepatocytes to survive to 6 hours, following a 30 minute pre-incubation 
with ABT it was not possible to get more data the effects of ABT in human 
hepatocytes. 
Surprisingly buspirone also demonstrated significant irreversible binding in rat 
hepatocyte incubations, although unlike nefazodone there was no impact on the 
viability of the hepatocytes. The irreversible binding of buspirone was much higher 
than that observed in rat liver microsomes (chapter 2). It is a possibility that 
buspirone irreversibly binds to cytosolic proteins found in hepatocytes and not to the 
CP450 enzymes found in the endoplasmic reticulum.  
It has previously been shown that nefazodone and buspirone both exhibit high levels 
of irreversible binding inhuman hepatocytes. In human hepatocytes it was calculated 
that the daily body burden of buspirone (3.8mg/kg) was actually higher than 
nefazodone (3.6mg/kg) due to the higher turnover of nefazodone to metabolites and 
hence a smaller fraction of the metabolites of nefazodone are reactive metabolites 
(Bauman et al. 2009). However, it is important to note that the irreversible binding of 
a drug to cellular protein does not necessarily lead to toxicity. 3-hydroxyacetanilide, 
a region-isomer of paracetamol, irreversibly binds to hepatic proteins in rodents 
without inducing hepatotoxicity. The difference in the location of the binding is 
important in this case, with 3-hydroxyacetanilide binding primarily to cytosolic 
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proteins, whilst paracetamol binds primarily to proteins in the mitochondria, which 
are important in regulating cell death (Tirmenstein, Nelson 1989). Nakayama et al, 
investigated the risk posed by irreversible binding using a using a zone classification 
system, which used daily dose and irreversible binding in human liver microsomes, 
human hepatocytes and rat liver in vivo (Nakayama et al. 2009). They identified that 
hepatocytes provided the best correlation between irreversible binding, dose and 
toxicity of the drug, however, the system still placed 7 out of 37 drugs (19%) in the 
wrong category. It is therefore important that irreversible binding studies are taken 
into consideration with a variety of other in vitro tests and the formation of reactive 
metabolites and irreversible binding alone is not used as an indicator of toxicity. 
Indeed a study that includes a panel of in vitro assays to determine likelihood of 
toxicity, identified nefazodone as a potential risk in all but one assay and of all the 
compounds tested it flagged the most warning signals for potential toxicity 
(Thompson et al. 2012). In this panel nefazodone gave positive results for all the 
identified ways that nefazodone could potentially cause toxicity, giving positive 
results for toxicity in THLE null cells as well as THLE CYP3A4 cells, demonstrated 
greater toxicity in galactose rather than glucose grown HepG2 cells and gave a 
positive result for the inhibition of BSEP in transporter assays (Thompson et al. 
2012). 
3.4.4 Mitochondrial toxicity 
The data that was gathered in cultured rat hepatocytes using Cellomics technology, 
indicated that 100µM nefazodone abolished the mitochondrial membrane potential, 
determined using TMRM, whilst buspirone had no effect on the mitochondria at 
equivalent concentrations. Nefazodone treatment also resulted in cell death that was 
characterised by nuclear condensation and disruption of cellular membrane potential. 
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Due to the time points used it is unclear whether mitochondrial involvement in 
nefazodone cell death was a result of direct or indirect mitochondrial toxicity, 
however, there is evidence that nefazodone is a mitochondrial toxin. Work done by 
Dykens et al showed that, in HepG2 cells, nefazodone had IC50 values of 38.4µM 
and 9µM in cells grown in glucose and galactose containing media respectively 
(Dykens et al. 2008). Cells grown in high glucose media are not dependent on ATP 
production through OXPHOS and are therefore less susceptible to mitochondrial 
toxicity. This can be revealed using cells grown in galactose media, where the cells 
are forced to undergo OXPHOS to produce their ATP requirements (Marroquin et al. 
2007). Further investigation identified that nefazodone inhibits complex I of the 
OXPHOS chain. Inhibition of complex I, which prevents electron flow to 
ubiquinone, leads to an accumulation of NADH which may lead enhanced formation 
of ROS and therefore cell death. The use of HepG2 cells to carry out these 
experiments, which have little or no CYP450 mediated metabolism, indicates that 
nefazodone itself, and not a reactive metabolite, is toxic to the mitochondria. 
3.4.3 BSEP inhibition 
The argument that nefazodone itself causes drug induced liver injury and not the 
reactive metabolite has been suggested previously and mechanisms of injury other 
than reactive metabolite formation and irreversible binding have been proposed. 
Kostrubsky et al, investigated the effect nefazodone had on the bile salt export pump 
(BSEP). Following experiments in vesicles expressing BSEP and using sandwich 
cultured hepatocytes to assess the transport of taurocholic acid into the canaliculi 
they found that the IC50 values were similar in both systems, and concluded that 
parent compound must be responsible for BSEP inhibition. Using sandwich cultured 
hepatocytes they also demonstrated that 24 hours post nefazodone dose, cells pre-
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incubated with ABT had a 45% decrease in protein synthesis, whereas hepatocytes 
treated with nefazodone alone had returned to the same levels as control values. 
They also found no evidence of a GSH conjugate in their system and concluded that 
this may be due to the high rate of glucuronidation and sulphation in the hepatocytes 
preventing the bioactivation of p-hydroxy metabolites (Kostrubsky et al. 2006).  
It is also a possibility that a combination of the above mechanisms is a possibility. 
Inhibition of BSEP and other export pumps could lead to an accumulation of bile 
salts which have also been shown to be mitochondrial toxins, leading to a collapse of 
the mitochondrial membrane potential and cell death. 
3.4.4 Conclusion 
The aim of this chapter was to determine whether there was a link between reactive 
metabolite formation, irreversible binding and toxicity of nefazodone in hepatocytes 
and compare this to the non-hepatotoxin buspirone.  
Following experiments with rat liver microsomes in chapter 2 it can be suggested 
that reactive metabolite formation might be responsible for the hepatotoxicity 
observed with nefazodone; i.e. the differences in the bioactivation potential of para-
hydroxy nefazodone and buspirone could explain the differences in the toxicity. 
However, experiments with hepatocytes suggest an alternative mechanism, as they 
do not support this conclusion. Indeed, analysis of the relationship between 
metabolism and toxicity suggest that the parent compound might be responsible. 
Other mechanistic possibilities by which nefazodone parent compound may cause 
hepatotoxicity are through inhibition of the BSEP transporter or through interference 
with the mitochondrial OXPHOS.   
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4.1 INTRODUCTION 
 
Phenformin is an anti-diabetic agent belonging to the biguanide class. It came to the 
market in the 1950s and quickly became the leading compound in its class due to its 
superior efficacy. Unfortunately it became apparent that phenformin was associated 
with an increased risk of lactic acidosis (lactate levels greater then 5mmol/L and 
serum pH of less than 7.35). This estimated to be between 40-64 cases per 100,000 
patient years (Bailey 1992), substantially higher than the 3.3 cases per 100,000 
patient years associated with metformin.  
Figure 4.1. Chemical structures of the biguanides. 
 The guanidinium group gives the biguanides a cationic charge at physiological pH. 
This coupled with the relatively high lipophilicity of phenformin it is able to be 
accumulated into mitochondria up to 100-fold against a concentration gradient 
(Davidoff 1971), probably via ΔΨ.  Phenformin has also been demonstrated to 
accumulate up to 61-fold in the liver of rats (Sogame et al. 2011) via OCT1 (Wang et 
al. 2002, Wang et al. 2003b, Sogame et al. 2009). An investigation carried out in 30 
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diabetic patients to try and clarify the relationship between serum biguanide levels 
and increased lactate concentrations could demonstrate no relationship between the 
serum biguanide level, administered dose and time of administration. There was also 
no correlation between biguanide levels and lactate increase. Whilst the serum levels 
were only slightly above the therapeutic range expected with phenformin, both liver 
and kidney concentrations of phenformin showed highly toxic levels of the drug 
(Irsigler, Kritz & Regal 1979), demonstrating that biguanide accumulation in the 
liver also occurs in humans. An accumulation in both the liver, followed by the liver 
mitochondria, could mean that mitochondrial concentrations reach several thousand 
fold that of plasma concentrations, causing interference with energy production and 
lactate metabolism through inhibition of complex 1 of the mitochondrial respiratory 
chain (El-Mir et al. 2000, Dykens, J.A., Jamieson, J., Marroquin, L., Nadanaciva, S., 
Billis, P.A., Will,Y. 2008, Owen, Doran & Halestrap 2000). In the case of 
phenformin this accumulation in the mitochondria could be further exacerbated by 
metabolism. 
Phenformin has been shown to be undergo hepatic metabolism to p-hydroxy 
phenformin in man, rats, guinea pigs and dogs (Shah, Evans & Oates 1985, Guest, 
King & Parke 1979, Alkalay, Volk & Roth 1979, Oates et al. 1982) and in man this 
metabolism takes place through CYP450 2D6 (Shah, Evans & Oates 1985, Oates et 
al. 1982). CYP450 2D6 is a highly polymorphic enzyme and this can lead to 
different patients outcomes treated with the same drug, ranging from a lack of 
clinical effect to severe toxicity. Perhaps one of the most well documented of these 
cases is that of perhexilene. Perhexilene is hydroxylated by CYP450 2D6 so that it 
can undergo excretion. However, PMs lack the capacity to metabolise perhexilene 
causing an accumulation of perhexilene in tissues, eventually leading to steatosis and 
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peripheral neuropathy. However, identification of CYP450 2D6 PMs and therapeutic 
drug monitoring has enabled this drug to be re-introduced in some countries. Table 
4.1 identifies other compounds that have been demonstrated to be metabolised by 
CYP450 2D6 and the clinical effect of polymorphisms in this enzyme (Shah, Oates 
& Idle 1982, Morgan, Reshef & Shah 1984). 
In a study of healthy volunteers given a single dose of phenformin a significant 
correlation between CYP450 2D6 PM phenotype and higher lactate levels has been 
demonstrated (Idle et al. 1981, Shah, Evans & Oates 1985, Shah et al. 1980). A 
combination of PM phenotype and accumulation in liver mitochondria could 
potentially lead to toxic concentrations of phenformin in the liver causing 
mitochondrial toxicity in the form of lactic acidosis. 
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Table 4.1. Clinical effects of CYP2D6 polymorphisms. CYP2D6 is responsible for the 
metabolism of 25% of drugs, therefore several important clinical consequences of CYP2D6 
polymorphisms are known to occur. These range from reduced efficacy through to severe 
toxicity. 
Recently, there has been a renewed interest in phenformin as an anti-cancer drug. 
AMPK activators, such as phenformin, have been demonstrated to induce either cell 
cycle arrest or apoptosis in various cell cancer lines of different genetic origin 
(Caraci et al. 2003, Appleyard et al. 2012, El-Masry, Brown & Dobson 2012). This 
has lead to phenformin being recommended for clinical trials for the treatment of 
ER-positive and triple negative breast cancer.  
The aims of this chapter were primarily to assess the biguanides as tools for 
investigations of mitochondrial toxicity in primary hepatocyte suspensions. Initially 
the propensity for the biguanides to dissipate the mitochondrial membrane potential 
Drug Indication Clinical effect of CYP2D6 polyporhism References
Perhexilene Anti-anginal Mono-hydroxylation of perhexilene
carried out almost exclusively by
CYP2D6. Accumulates in PMs leading
to steatosis and peripheral neuropathy.
Shah et al, 1982;
Morgan, Reshef,
Shah,1984.
Haloperidol Anti-psychotic PMs show an increased risk of
pseudoparkinsonism and over-sedation,
whilst lower therapeutic efficacy is seen
with an increasing number of active
CYP2D6 genes.
Brockmöller et
al, 2002; Spina
et al, 1992.
Tamoxifen Anti-cancer Pro-drug tamoxifen is metabolised to its
active form endoxifen by N-
demethylation and 4-hydroxylation, both
reactions carried out by CYP2D6. A
smaller therapeutic effect is observed in
PMs.
Sterns and Rae,
2008.
Phenformin Anti-diabetic Lack of hydroxylation via CYP2D6
leads to higher plasma lactate levels and
increased risk of lactic acidosis.
Idle et al, 1981,
Shah et al, 1980;
Shah et al 1985
Tramadol Analgesic Tramadol undergoes O-demethylation to
O-desmethyltramadol, which is 200
times more potent at the µ opiod
receptors. In PMs tramadol has been
reported to have a much lower analgesic
effect.
Stamer et al,
2007
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was established in cultured hepatocytes using TMRM. This allowed phenformin to 
be taken forward as a tool for assessing mitochondrial dysfunction in primary 
hepatocytes. 
4.2 MATERIALS AND METHODS  
4.2.1 Materials 
Phenformin, quinine and quinidine were purchased from Sigma-Aldrich (Poole, 
UK). ATP assay was purchased from Promega (UK). Collagenase type II was 
purchased from Worthington Biochemical Corporation. Cellomics dyes, Hoechst 
33342, TMRM and TO-PRO 3 iodide, and 10x HBSS were all purchased from 
Invitrogen (UK). Lactate assay was purchased from Sigma-Aldrich (Poole, UK). 
Biocoat collagen coated plates were purchased from VWR (UK). Solvents were 
purchased from Fischer Scientific and were all HPLC grade and above. All other 
reagents were purchased from Sigma-Aldrich (Poole, UK) unless otherwise stated.  
4.2.2. Rat hepatocyte isolations for suspension hepatocytes 
Rat hepatocytes were isolated from male Wistar rats as in chapter 3.2.2 and only 
used if viability was greater than 80% as assessed by trypan blue exclusion. 
4.2.3 Suspension hepatocyte incubations 
Hepatocytes were incubated with 50-1000µM phenformin in the absence and 
presence of 100µM quinine for 6 hours in incubation buffer and only used if control 
values were greater than 60% as assessed by trypan blue exclusion at 6 hours. After 
6 hours viability was assessed using trypan blue exclusion and ATP content and 
samples for metabolism were taken. 
4.2.4 Cultured hepatocyte isolation 
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Hepatocytes isolated at Pfizer for hepatocyte culture were isolated as in chapter 
3.2.11. 
4.2.5.Cellomics analysis 
Hepatocytes were dosed with 0-200µM phenformin dissolved in basal media for 24, 
48 or 72 hours. At each time point the media was removed and replaced with basal 
media containing Hoechst 33342 (1 in 10000), TMRM (1 in 200) and TO-PRO 3 
iodide (1 in 1000). Plates were then returned to the incubator for 20 minutes to allow 
uptake of the dyes. The plates were then read using Cellomics technology.  
4.2.6. HPLC and LC-MS sample preparation 
At the end of the incubation period samples were stopped by the addition of an equal 
volume of ice-cold ACN and were then stored at -20°C overnight to precipitate 
protein. The samples were then spun at 2200rpm for 10 minutes and the supernatant 
removed. The supernatant was then dried down under a gentle stream of nitrogen 
gas. Once the samples were dried they were reconstituted in 300µl dH2O and 
centrifuged twice at 14,000 rpm for 5 minutes to remove any remaining debris. The 
samples were then run on either the HPLC or mass spec. Samples not run 
immediately were stored at -20°C until analysis. 
4.2.7 HPLC method 
The HPLC system consisted of a Phenomenex Gemini-NX C18 column 
(4.6x250mm, 5µ), a Dionex HPLC, with auto-sampler and UV detection which was 
set at 236nm. The mobile phase consisted of 0.1% formic acid (A) and 90% 
methanol 10% ACN (B) with a flow rate of 0.9ml/min. A step wise gradient was run 
beginning at 5% B and rising to 30% B at 10 minutes.  This was then increased 
further to 70% B at 15 minutes and 100% B at 16 minutes. It was held at 100% B for 
140 
 
Phenformin: Parent compound and its role in mitochondrial toxicity 
1 minute before being returned to 5% B at 18 minutes. The column was then left to 
re-equilibrate for the next sample until 25 minutes. 
4.2.8. LC-MS method 
LC-MS analysis was undertaken with an API2000 attached to a Perkin-Elmer LC 
system. The LC method was the same as section 4.2.7. The MS was operated in 
positive ion mode. The operating parameters are in table 4.2 below. 
Table 4.2. Operating parameters for phenformin mass spectrometry. 
4.2.9 Lactate measurement 
Lactate was measured using a Lactate Assay Kit from Sigma-Aldrich. Samples were 
snap frozen in liquid nitrogen and stored at -80°C until needed. 200µl of sample was 
vortexed and centrifuged at 14,000rpm for 10 minutes to remove insoluble material. 
The sample was then passed through a 10kDa cut-off spin filter to remove any 
lactate dehydrogenase. The lactate was then measured according to manufacturer’s 
instructions. 
4.2.10 Animal work 
All animal work was undertaken in accordance with Home Office regulations and 
local ethics committee procedures. 
CUR 30.00
IS 5000V
TEM 400°C
GS1 30
GS2 75
DP 100
FP 250
EP 10
141 
 
Phenformin: Parent compound and its role in mitochondrial toxicity 
4.2.11 Statistical analysis 
Statistical analysis was undertaken using Stats Direct software. Data was tested for 
normality using a Shapiro-Wilk test and either a Student’s T test (parametric) or 
Mann Whitney U test (non-parametric) was used to make comparisons between data 
sets. An ANOVA (Dunnett’s comparison to control), for parametric data, or 
Kruskall-Wallis, for non-parametric data, was used to determine significance to 
control values. 
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4.3 RESULTS 
4.3.1 Effect of the biguanides on mitochondria in cultured rat hepatocytes 
 
The effects of the biguanides on cytotoxicity and the mitochondrial membrane 
potential were assessed using cultured rat hepatocytes and Cellomics analysis (figure 
4.2-4.). The hepatocytes were incubated with 0-200μM of metformin, buformin or 
phenformin for 24-72 hours. Cytotoxicity was assessed using Hoechst 33342 and the 
mitochondrial membrane potential using TMRM. Metformin did not induce either 
significant toxicity or dissipation of the mitochondrial membrane potential at any 
concentration or time point (figure 4.2). 200μM buformin was significantly cytotoxic 
at all time points (24 hours, 146.238± 11.882 % control; 48hours, 306.575±19.359 % 
control; 72 hours, 290.312±59.216 % control) but only depleted the mitochondrial 
membrane potential at 48 and 72 hours (48 hours, 24.241±7.391 % control; 72 hours, 
2.356 ± 0.769) (figure 4.3). 200μM phenformin showed significant cytotoxicity at all 
time points but no other concentration of phenformin demonstrated significant 
toxicity (figure 4.4). The mitochondrial membrane potential was significantly 
decreased in hepatocytes dosed with 200μM phenformin at 24 hours (1.028 ±0.39 % 
control) and 48 hours (2.13 ± 0.32 % control). At 72 hours phenformin demonstrated 
loss of mitochondrial membrane potential at 50μM (60.50 ± 5.98 % control), 100μM 
(65.08 ± 3.59 % control) and 200μM (3.21 ± 1.21 % control). The significant 
depletion of mitochondrial membrane potential before onset of cytotoxicity implies 
that in cultured hepatocytes the dissipation of the mitochondrial membrane potential 
is a possible cause of cell death. Based on these results phenformin was taken 
forward to use as a tool for the assessment of mitochondrial toxicity in primary rat 
hepatocytes. 
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Figure 4.2. Cellomics analysis of metformin in cultured rat hepatocytes. (A) Hoechst staining for cytotoxicity metformin. (B) TMRM intensity in hepatocytes treated with metformin. Data is % control values and is expressed as mean ± SEM. Data is from 3 independent isolations.  
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Figure 4.3. Cellomics analysis of buformin in cultured rat hepatocytes. (A) Hoechst staining for cytotoxicity of buformin. (B) TMRM intensity in hepatocytes treated with buformin. Data is % control values and is expressed as mean ± SEM. Data is from 3 independent isolations. Significance was determined using ANOVA  (Dunnett’s comparison to control) ***P<0.001 24hours; ‡P<0.05 ‡‡‡P<0.001 48 hours; †††P<0.001 72 hours. 
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Figure 4.4. Cellomics analysis of phenformin in cultured rat hepatocytes. (A) 
Hoechst staining for cytotoxicity of phenformin. (B) TMRM intensity in hepatocytes treated with phenformin. Data is % control values and is expressed as mean ± SEM. Data is from 3 independent isolations. Significance was determined using ANOVA  (Dunnett’s comparison to control) ***P<0.001 24hours; ‡‡‡P<0.001 48 hours; † P<0.05 ††P<0.01 †††P<0.001 72 hours. 
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4.3.2 The investigation of metabolism of phenformin in primary rat 
hepatocytes 
 
The metabolism of phenformin was determined in freshly isolated suspension rat 
hepatocytes between 50-1000µM.  In this system phenformin was completely turned 
over at concentrations of 200µM and less to 3 metabolites (M1-M3) demonstrated in 
figure 4.6. Metabolites M1-M3 were all identified through searches for m/z 60, 
[C(NH2)3]+, a fragment ion distinctive to the biguanide class of drugs (figure 4.5). 
All 3 of these metabolites were discovered to be glucuronides. M1 (m/z 398) was 
determined to be an [OH] phenformin glucuronide and is assumed to be the 4’-OH-
phenformin that has previously been identified. Novel metabolites M2 (m/z 414) and 
M3 (m/z 428) were determined to be a [2OH] phenformin glucuronide and a [OH, 
OMe] phenformin glucuronide respectively.  
At concentrations greater than 200µM the metabolism of phenformin to both phase I 
and phase II metabolites became saturated. In these samples the phase I aglycones of 
the glucuronide metabolites M1 and M3 could be identified (figure 4.7). In samples 
containing 1000µM phenformin the phase I metabolites [OH] phenfomin (M4) and 
[OH, OMe] phenformin (M5) were determined. Again the [OH] metabolite is 
assumed to be 4’-OH-phenformin. The fragment ions of each of the metabolites can 
be found in table 4.3. 
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Figure 4.5. Product ion spectra of [M+H]+ ions of phenformin. Important 
fragments are highlighted in brackets. 
 
Table 4.3. Fragment ions of phenformin metabolites identified in freshly 
isolated rat hepatocytes.  
Metabolite m/z Fragment ions
M1 [OH] phenformin
glucuronide
398 60.2, 121.1, 180.0, 205.0, 222.0, 
398.1
M2 [2OH] phenformin
glucuronide
414 137.1, 196.0, 218.1, 238.1, 414.1
M3 [OH, OMe] phenformin
glucuronide
428 60.1, 121.1, 151.1, 210.1, 222.1, 
235.1, 252.1, 398.0, 428.1
M4 [OH] phenformin 222 60.1, 77.1, 91.1, 93.1, 103.1, 121.1, 
180.1, 222.0
M5 [OH, OMe] phenformin 252 60.1,  91.2, 119.2, 151.0, 252.1
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Figure 4.6. Representative traces of 100μM phenformin metabolites identified in rat hepatocytes. (A) Extracted ion current m/z 60 (B) 
[OH] phenformin glucuronide (m/z 398) (C) [2OH] phenformin glucuronide (m/z 414) (D) [O, OMe] phenformin glucuronide. 
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Figure 4.7. Representative traces of 1000μM phenformin metabolites identified in rat hepatocytes. (A) XIC m/z 398 [OH] phenformin 
glucuronide. (B) XIC m/z 222 [OH] phenformin. (C) XIC 428 [OH, OMe] phenformin glucuronide. (D) XIC m/z 252 [OH, OMe] phenformin.  
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4.3.3 Investigations of quinine and quinidine as CYP450 2D inhibitors in 
rat hepatocytes 
Quinidine is a well known CYP450 2D6 inhibitor in humans and is widely used in 
both human and rodent samples. However, it has been reported that its stereoisomer 
quinine is a more potent CYP450 2D inhibitor in the rat. To investigate the 
inhibitory properties of quinine and quinidine on phenformin metabolism, inhibition 
studies were undertaken in the rat hepatocytes and the metabolism assessed using 
HPLC and LC-MS. Quinine was clearly the most effective inhibitor of phenformin 
in rat hepatocytes (figure 4.9 and 4.10) with only small amounts of metabolites 
detectable using HPLC and LC-MS.. Additionally, it appears to partially inhibit the 
glucuronidation of the small amount of hydroxyphenformin that was produced. 
Based on the intensity of metabolite peaks quinidine (figure 4.8 and 4.12) was much 
less effective as an inhibitor of phenformin hydroxylation than quinine (figure 4.11.). 
It did, however, completely prevent further oxidation of hydroxyphenformin to the 
catechol intermediate. Like quinine, it also appeared to inhibit glucuronidation of the 
hydroxyphenformin that was formed. 
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Figure 4.10. Inhibition of phenformin metabolism by quinine in rat hepatocytes. (A) TIC of phenformin and quinine in rat hepatocytes (B) XIC m/z 60. 
(C) XIC m/z 206 phenformin. 
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Figure 4.11. Inhibition of phenformin metabolism by quinidine in rat hepatocytes. (A) TIC of phenformin and quinidine in rat hepatocytes. (B) XIC m/z 
60 [C(NH2)3] (C) XIC m/z 206 phenformin. 
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4.3.4. Effect of CYP2D inhibition on turnover of phenformin in suspension 
rat hepatocytes 
The inhibition of the turnover of 0-1000µM phenformin by quinine (100µM) was 
assessed using HPLC (figure 4.13). The difference between the AUC of phenformin 
in samples without and with quinine was investigated. Quinine had a significant 
effect on the turnover of phenformin in hepatocytes dosed with 100µM (0 ± 0 
without quinine vs 318.03 ± 87.85 with quinine) and 200µM (47.30 ± 47.30 without 
quinine vs 648.80 ± 121.28 with quinine) phenformin. Quinine also seemed to have 
an effect at 500µM (714.90 ± 214.91 without quinine vs 1128.89 ±68.38 with 
quinine) 1000µM (13320.96 ±48.11 without quinine vs 1400.17 ± 26.67 with 
quinine) but this was not significant (figure 4.12). 
Figure 4.12. Effect of quinine on the turnover of phenformin in rat hepatocytes.  
Hepatocytes were treated with 0-1000µM phenformin in the presence of quinine (100µM) 
and the difference in turnover assessed by AUC of phenformin peak. Data is mean AUC ± 
SEM from four independent isolations. Statistical significance was determined using a Mann 
Whitney U test. *P<0.05 
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4.3.5 Effects of CYP2D6 inhibition on the toxicity of phenformin in 
suspension rat hepatocytes 
The effect of 0-1000µM phenformin on the viability of suspension was investigated 
in the presence and absence of quinine using trypan blue exclusion (figure 4.13.). 
Quinine concentrations of 0-100μM were initially tested for cytotoxicty and it was 
determined that none of these concentrations were cytotoxic. The viability of 
hepatocytes treated with 100μM quinine after 6 hours were 101.28±2.89% control 
(n=4).  Phenformin was only significantly cytotoxic to hepatocytes at 500μM and 
above, however when the hepatocytes were incubated in the presence of quinine only 
1000μM phenformin was significant compared to control values. This demonstrated 
a trend towards decreased cell viability when cells were incubated in the presence of 
quinine but this decrease was not significant at any concentration.  
Figure 4.13. Cell viability of hepatocytes treated with phenformin in the presence (○) 
and absence (●) of phenformin. Data is expressed as mean ± SEM % control and are from 
7 independent isolations. Significance to control was determined using Kruskall-Wallace 
*P<0.05. Significance between data points was determined using Mann Whitney U test but 
the difference between the data was not significant. 
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4.3.6. Effect of phenformin on lactate levels in suspension hepatocytes 
The lactate levels of hepatocytes treated with phenformin did not appear to increase 
until 1000µM phenformin when lactate concentrations were elevated 3.2 fold that of 
control values. When phenformin was incubated with quinine the lactate 
concentration of the cell was considerably higher than with phenformin alone. The 
most noticeable difference was at 500μM phenformin where the lactate 
concentration in the presence of quinine was 2.7 fold that of phenformin alone 
(figure 4.14). 
Figure 4.14. Concentration of lactate in hepatocytes treated phenformin in the presence 
(○) and absence (●) of quinine. Data is expressed as ng/µl and is mean ± SEM from two 
independent isolations. 
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4.4 DISCUSSION 
 
The principal aims of this chapter were to establish whether there was a link between 
inhibition of phenformin metabolism and mitochondrial toxicity. Phenformin had a 
high turnover in rat hepatocytes, which could be inhibited with inclusion of quinine 
in the incubation. Increased phenformin concentrations in hepatocytes, as measured 
by HPLC, correlated with an increase in lactate concentrations. In cultured 
hepatocytes there was also evidence that phenformin dissipates the mitochondrial 
membrane potential which may have a role in phenformin induced lactic acidosis. 
Phenformin was metabolised in rat hepatocytes to five detectable metabolites. At 
lower concentrations of phenformin (<200μM) the metabolites consisted completely 
of glucuronides and it was only when the concentration became high enough to 
saturate metabolism (>200μM) that the aglycones of the glucuronide metabolites 
became detectable. Previous studies of phenformin metabolites have only identified 
hydroxyphenformin and the corresponding glucuronide as metabolites (Guest, King 
& Parke 1979, Alkalay, Volk & Roth 1979). In rat hepatocytes, however, 
hydroxyphenformin underwent both further hydroxylation and methylation reactions. 
Whether these metabolites would be formed in vivo or whether the reduced 
environment of hepatocyte suspension leads to further metabolic transformations 
remains to be seen.  
Plasma concentrations of phenformin do not always correlate with an onset of lactic 
acidosis (Irsigler, Kritz & Regal 1979). The identification of OCT1 in the transport 
of metformin (Sogame et al. 2009) and more recently the accumulation of 
phenformin in the liver of rats leading to concentrations 61-fold those in the serum 
(Sogame et al. 2011) suggest that the source of lactic acidosis may be in the liver, 
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this is supported by a case study that estimated that liver concentrations were 24-26 
fold that of serum phenformin concentrations (Irsigler, Kritz & Regal 1979). Lactate 
concentrations in hepatocytes increased >3-fold in hepatocytes treated with high 
(1000μM) concentrations of phenformin, compared to control.  
Studies of metabolism of phenformin in humans showed that phenformin 
hydroxylation was mediated by the same enzyme as debrisoquine (Shah, Evans & 
Oates 1985, Shah et al. 1980, Oates et al. 1982), which is now known to be CYP450 
2D6. CYP450 2D6 is responsible for the metabolism of approximately 25% of 
drugs, but is highly polymorphic.  The population can be split into 4 metabolising 
groups, poor metabolisers (PMs), intermediate metabolisers (IMs), extensive 
metabolisers (EMs) and ultra-rapid metabolisers (UMs) (Ingelman-Sundberg 2005). 
CYP2D6 polymorphisms significantly affect the pharmacokinetics of approximately 
50% of the CYP2D6 substrates that are used in the clinic (Ingelman-Sundberg 2005), 
some of the clinical consequences of CYP450 2D6 polymorphisms are demonstrated 
in figure 4.2. Patients with PM phenotype, which account for approximately 7% of 
the Caucasian population (Bradford 2002, Sachse et al. 1997), are more likely to 
develop toxicity due to higher drug plasma or organ concentrations whilst UMs, 1-
2% of the Caucasian population (Bradford 2002), are more likely to suffer as a result 
of lack of efficacy or toxicity resulting from the production of a toxic metabolite. To 
mimic poor metaboliser phenotype in vitro, the metabolism of phenformin was 
inhibited using quinine in rat hepatocytes. Including quinine in the incubations 
significantly increased hepatocyte phenformin concentrations. The increase in 
phenformin concentration was associated with enhanced hepatocyte lactate 
concentrations. At concentrations of 200-500μM phenformin incubated with quinine 
the lactate concentration increased >x2 phenformin alone.   
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As demonstrated in cultured rat hepatocytes, phenformin dissipated the 
mitochondrial membrane potential as measured by TMRM. As phenformin exists in 
its cationic form at physiological pH, it is a possibility that phenformin can 
accumulate in the mitochondria against the concentration gradient due to ΔΨm 
(Davidoff 1971).  Accumulation of other lipophilic cationic drugs such as 
perhexilene and amiodarone, cause ‘OXPHOS uncoupling’, which results in a 
reduction of ATP-synthesis as the re-entry of protons within the mitochondrial 
matrix bypasses ATP synthase. This explains why the toxicity of the biguanides 
correlates with lipophilicity, with the most polar biguanide, metformin, the only one 
to remain on the market. Furthermore, the biguanides are also capable of inhibition 
of complex I of the mitochondrial transport chain (Dykens, J.A., Jamieson, J., 
Marroquin, L., Nadanaciva, S., Billis, P.A., Will,Y. 2008, Owen, Doran & Halestrap 
2000)J.A. et al. 2000).  It has been established that inhibition of complex I leads to 
inhibition of gluconeogenesis (Owen, Doran & Halestrap 2000). PM phenotype 
followed by successive accumulation into the liver and then the mitochondria could 
therefore lead to a concentration of phenformin in the mitochondria several thousand 
fold that in the serum. This could be enough to inhibit complex I sufficiently to 
induce lactic acidosis. 
The inhibition of gluconeogenesis by the biguanides is part of their primary 
pharmacology. The inhibition of complex I and OXPHOS uncoupling by the 
biguanides alters the AMP:ATP ratio which activates AMPK.  AMPK becomes 
activated when the AMP:ATP ratio is altered in favour of AMP, normally during 
cellular stress, such as hypoxia and ischemia, when ATP production drops. The 
AMPK pathway leads to the activation of glycolysis for ATP production and the 
inhibition of gluconeogenesis. This helps to reduce blood glucose levels in diabetics, 
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hence controlling hyperglycaemia (Hawley et al. 2002, Zhou et al. 2001). However, 
in PM phenotypes the concentration of phenformin may be enough to inhibit 
gluconeogenesis to the extent where lactic acidosis is induced. 
Recently, the interest in phenformin has been renewed, due to the reports of its 
potential uses as chemotherapeutic agent for cancer treatment. AMPK activators 
such as phenformin, can induce apoptosis or cell-cycle arrest in various cancer cell 
lines of different genetic origin (Caraci et al. 2003, Appleyard et al. 2012, El-Masry, 
Brown & Dobson 2012). As a result phenformin has been recommended for clinical 
trials in the treatment of ER-positive and triple negative breast cancer. Genotyping 
patients for CYP450 2D6 phenotype could help to improve the treatment regimen of 
patients receiving phenformin and result in a safer re-introduction into the clinic. In 
conclusion, increased phenformin concentrations achieved by inhibition of CYP450 
2D in rat hepatocytes does lead to increased lactate concentrations. This 
demonstrates the importance of the liver concentration of phenformin in inducing 
lactic acidosis in patients.  
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5.1 INTRODUCTION 
 
Adverse drug reactions (ADRs) are a major problem to pharmaceutical companies 
and health services alike. They account for the attrition of drugs during pre-clinical 
development as well as the withdrawal of marketed drugs. In the UK, it is reported 
that 6.5% of hospital admissions are attributable to ADRs (Pirmohamed et al. 2004). 
ADRs can affect any system within the body; however, the liver is frequently a 
target of drug toxicity. Drug induced hepatotoxicity is the most cited cause for the 
removal of drugs from the market and is hard to predict from pre-clinical and clinical 
testing (Jaeschke et al. 2002).  Clinical surveillance in the US has indicated that 50% 
of acute liver failures are due to drugs. The majority (36%) are caused through 
paracetamol overdose but 16% of these are idiosyncratic reactions (Ostapowicz et al. 
2002).  
It is widely accepted that bioactivation plays a role in drug induced liver injury. The 
ability of a drug to become bioactivated is a function of its chemistry and the 
structural alerts that lead to bioactivation are well defined (Kalgutkar et al. 2005a). 
Despite this, the potential of a drug to be bioactivated and cause toxicity is a 
complex one and many drugs are bioactivated but are not hepatotoxic. Idiosyncratic 
hepatotoxicity caused by bioactivation is likely to be due to where the drug binds in 
the cell as well as a function of the patient’s biology. This uncertainty in the role of 
bioactivation and irreversible binding makes it difficult to predict which drugs will 
be toxic. Further investigations into the roles of bioactivation and mechanisms of 
toxicity need to be further established.  
There is a growing awareness of the role of mitochondria in drug toxicity. Drugs 
such as troglitazone, diclofenac, nimesulide, valproic acid and amiodarone are all 
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now known to involve a mitochondrial component in their toxicity. Drugs can affect 
the mitochondria through a variety of mechanisms, with many causing mitochondrial 
damage through a mixture of these. Mitochondrial dysfunction often affects the liver 
due to the high concentrations of xenobiotics to which the liver is exposed. Of the 
drugs removed from the market due to hepatotoxicity, mitochondrial toxicity will be 
involved in several cases (Dykens, J.A. and Will, Y et al. 2007).  
The aims of this thesis were two-fold: 
1. To investigate the role of bioactivation in nefazodone cytotoxicity (chapters 2 
and 3).  
This led to the characterisation of the bioactivation pathway of nefazodone in both 
rat and human liver microsomes. The ability of nefazodone to irreversibly bind to 
hepatic protein was assessed and the formation of quinone-imines was identified 
through GSH trapping. The bioactivation of nefazodone was further investigated in 
freshly isolated rat and human hepatocyte suspensions. Assessment of reactive 
metabolite formation, irreversible binding, total GSH content and cytotoxicity 
revealed that the parent compound was more cytotoxic towards hepatocytes than its 
metabolites. 
2. To investigate mechanisms underlying mitochondrial toxicity (chapter 4) 
The known mitochondrial toxins, the biguanides, were selected for these studies. 
Phenformin, in particular, was investigated due to the greater cytotoxicity observed 
in cell line and cultured hepatocytes (chapter 4) vs the other biguanides (Dykens et 
al. 2008). Difficulties of assessing parent compound cytotoxicity in freshly isolated 
hepatocytes had to be taken into account (due to the higher metabolic capability vs 
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cell lines); therefore, studies into the metabolism of phenformin were undertaken. 
Also, cytotoxicity and lactic acid formation was examined in the presence and 
absence of CYP450 2D inhibition, as phenformin causes lactic acidosis rather than 
overt hepatotoxicity in the clinic. 
Bioactivation, irreversible binding and mitochondrial liability in in vitro models can 
give hazard signals with specific compounds, but as this work demonstrates, the 
complete mechanism must be examined using both model compounds and non-toxic 
analogues, in order to gain a more thorough pathogenesis. This emphasises the fact 
that although knowledge of in vitro liabilities of compounds can help in pre-clinical 
decision making, attrition of a compound during pre-clinical testing, for example, 
due to bioactivation potential alone could prevent the development of useful drugs. 
This highlights the need for a battery of tests in pre-clinical decision making 
involving both reactive metabolite formation and mitochondrial toxicity. 
 
5.2 EXPLORING THE DIFFERENCES BETWEEN NEFAZODONE AND 
BUSPIRONE CYTOTOXICITY. 
 
The ability of nefazodone, but not buspirone, to be bioactivated is thought to be the 
reason for the difference in their safety profiles (Kalgutkar et al. 2005b). Nefazodone 
has also been associated with mitochondrial dysfunction (Dykens et al. 2008) and 
transporter inhibition (Kostrubsky et al. 2006) and these studies identified parent 
compound as the toxic agent (figure 5.1). The aims of this section of work were to 
establish the link between nefazodone bioactivation and cytotoxicity. 
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The work carried out in chapter 2 demonstrated the bioactivation of nefazodone. In 
supplemented rat and human liver microsomes, GSH conjugates of nefazodone were 
identified. Significant irreversible binding of radiolabelled nefazodone to rat liver 
microsomes also confirmed bioactivation. In concordance with other studies  
 
Figure 5.1. Proposed mechanisms of nefazodone mediated liver injury. There are three 
proposed mechanisms of nefazodone mediated liver injury in the literature. Nefazodone can 
undergo bioactivation to a quinone-imine that may cause hepatotoxicity through covalent 
binding to protein. Nefazodone has also been shown to inhibit complex I of the OXPHOS 
chain and BSEP in vitro, independently of hepatic metabolism. 
(Kalgutkar et al. 2005b), GSH conjugates of buspirone were not identified, even 
though para hydroxylation was deemed to have taken place. Buspirone did exhibit 
significant NADPH dependent irreversible binding as compared to control values, 
however, this was several fold lower than the binding displayed by nefazodone. 
From these studies it did appear as though the bioactivation of nefazodone, but not 
buspirone could be the cause of cytotoxicity, however, liver microsomes do not 
contain a full complement of metabolising enzymes. Therefore, the use of primary 
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hepatocytes was employed to investigate the bioactivation and cytotoxicity of 
nefazodone and buspirone (chapter 3). 
Metabolism studies carried out in primary rat hepatocytes did not identify any GSH 
conjugates of nefazodone, despite their previous discovery in liver microsomes. It is 
postulated that this is due to a high rate of glucuronidation and sulfation prevailing 
over bioactivation and GSH conjugation. As with liver microsomes buspirone did 
not produce a GSH conjugate. Despite a lack of GSH conjugation both nefazodone 
and buspirone both displayed significant irreversible binding over time. Buspirone 
also caused significant GSH depletion without causing a reduction in cell viability 
until concentrations reaching 1mM (200,000x serum Cmax). In contrast, the increase 
in irreversible binding of nefazodone and corresponding decrease in cell viability 
seemed to indicate that bioactivation was a possible mechanism for cytotoxicity. The 
use of the CYP450 inhibitor, ABT, decreased irreversible binding but paradoxically 
decreased cell viability. In this primary rat hepatocyte model of nefazodone toxicity 
it was therefore deemed that reactive metabolite formation was not the cause of 
cytotoxicity.  
Nefazodone cytotoxicity was also assessed in primary human hepatocytes. In human 
hepatocytes nefazodone exhibited similar cytotoxicity to rat hepatocytes. 
Metabolism studies were also undertaken and as with rat hepatocytes, no GSH 
conjugates of nefazodone were identified. Due to the limitations of the availability of 
liver and suitable hepatocyte isolations, inhibition of nefazodone metabolism using 
ABT could only be carried out once, but this demonstrated the same pattern of 
increased cytotoxicity as in rat hepatocytes. 
 
169 
 
Concluding discussion 
Table 5.1.The clinical presentation of nefazodone induced liver injury. 
Drug induced hepatotoxicity can mimic natural disease processes making a diagnosis 
of DILI difficult. Bioactivation and/or mitochondrial dysfunction are generally 
thought to be an initiating factor and it is a possibility that in humans a mixture of 
causes for nefazodone hepatotoxicity exist (table 5.1). Case studies indicate that the 
onset of nefazodone injury occurs between 4 and 28 weeks after initiation of 
nefazodone treatment and patients presented with symptoms of jaundice and malaise 
(Aranda-Michel et al. 1999, Aranda-Michel et al. 1999, Lucena et al. 1999, Eloubeidi, Gaede 
& Swaim 2000, Schirren, Baretton 2000, Tzimas, Dion & Deschênes 2003). 
Histopathological findings from patients with liver injury suggest that the 
idiosyncratic reaction in patients is due to mixed aetiologies. Centrilobular necrosis, 
which is commonly associated with DILI, was identified in all patients. Many 
patients also exhibited cholestasis, demonstrating a disruption of bile flow, possibly 
through an inhibition of BSEP by nefazodone. Some patients also had ballooning 
Type of reaction Effect on cells Seen with
nefazodone
Hepatocellular Direct effect or production by enzyme-drug adduct leads 
to cell dysfunction, membrane dysfunction, cytotoxicT-
cell response
Yes
Cholestasis Injury to canalicular membrane and transporters Yes
Immunoallergic Enzyme-drug adducts on cell surface induce IgE response No
Granulomatous Macrophages, lymphocytes infiltrate hepatic lobule Yes
Microvesicular fat Altered mitochondrial respiration, β-oxidation leads to 
lactic acidosis and triglyceride accumulation
No
Steatohepatitis Multifactorial Yes
Autoimmune Cytotoxic lymphocyte response directed at hepatocyte
membrane components
No
Fibrosis Activation of stellate cells Yes
Vascular collapse Causes ischemic or hypoxic injury Yes
Oncogenesis Encourages tumour formation No
Mixed Cytoplasmicand canalicular injury, direct damage to bile 
ducts
Yes
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degeneration, which is commonly seen in patients with non-alcoholic steatohepatitis, 
and is, therefore, likely to be as a result of mitochondrial damage to the cell.  
Whilst it can be concluded that in rat hepatocytes reactive metabolite formation is 
not responsible for cytotoxicity, it very difficult to extrapolate this to the clinic. The 
mechanism of nefazodone hepatotoxicity in patients could not be fully elucidated 
and it is likely that, in humans, nefazodone toxicity is mediated through a variety of 
different mechanisms. The case of buspirone also highlights that whilst it is 
important to be aware of the irreversible binding and bioactivation potential of a 
compound, irreversible binding alone should not be used as a determining factor for 
drug failure in pre-clinical safety testing.  
5.3 THE USE OF THE BIGUANIDES AS MODEL COMPOUNDS TO STUDY 
MITOCHONDRIAL TOXICITY 
 
There is an ever increasing awareness of the involvement of the mitochondria in 
DILI. Mitochondria can be involved in DILI either as a direct target of toxicity or 
indirectly through initiation of cell death pathways.  This is highlighted through the 
association of nefazodone with mitochondrial liabilities. However, due to the 
complex nature of nefazodone metabolism it is not an ideal compound for 
investigating mitochondrial toxicity and, therefore, the known mitochondrial toxins, 
the biguanides, were chosen as tools for exploring mitochondrial toxicity in primary 
hepatocytes.  
Initially, work was carried out to investigate the effect of the biguanides on the 
mitochondrial membrane potential in cultured hepatocytes. In agreement with the 
literature (Dykens et al. 2008), this showed that phenformin and buformin were the 
most potent inducers of mitochondrial dysfunction and cytotoxicity, hence it was 
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decided that phenformin should be taken forward to study mitochondrial 
dysfunction. Investigations in primary hepatocytes have to take into account hepatic 
metabolism and consequently initial investigations explored the metabolism of 
phenformin. The turnover of phenformin in rat hepatocytes was high and consisted 
mainly of hydroxylation and subsequent glucuronidation. Previous investigations 
into the metabolism of phenformin identified 4-hydroxy phenformin and the 
corresponding glucuronide as the metabolites of phenformin (Guest, King & Parke 
1979, Alkalay, Volk & Roth 1979) but in rat hepatocytes further hydroxylation and 
O-methylation reactions took place.  
Previously, studies have identified CYP450 2D6 as being responsible for the 
metabolism of phenformin in man. CYP450 2D6 is highly polymorphic and it has 
been reported that people with a CYP450 2D6 poor metaboliser phenotype, have 
higher serum lactate concentrations (Idle et al. 1981, Shah, Evans & Oates 1985, 
Shah et al. 1980, Oates et al. 1982). To mimic CYP450 2D6 poor metaboliser 
phenotype in the rat hepatocytes, phenformin was co-incubated with quinine. 
Inhibition of metabolism did not significantly decrease the cell viability of 
hepatocytes incubated with phenformin; however, as phenformin is not an overt 
hepatotoxin this was not a surprising result. The enhanced phenformin 
concentrations arising from inhibition of CYP450 2D did correspond with an 
increase in lactate production in hepatocytes.  
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5.4 FUTURE INVESTIGATIONS: BIOACCUMULATION IN THE 
MITOCHONDRIA 
 
It has long been established that compounds can accumulate in the mitochondria via 
the mitochondrial membrane potential. Fluorescent dyes, such as TMRM, use the 
mitochondrial membrane potential to accumulate in the mitochondria where they 
lose their positive charge and fluoresce. These dyes are commonly used to assess the 
presence of a mitochondrial membrane in isolated mitochondria and intact cells. 
However, cationic lipophilic compounds are able to accumulate in the mitochondria 
in the same way. In fact, as mitochondrial ΔΨ can be as great as -180mV, as much as 
a 1000-fold concentration gradient can form across the inner membrane (Dykens et 
al.2008). Lipophilic anionic compounds do not cross as easily into the mitochondria 
as they are restricted by the outer membrane, but once inside the inter-membrane 
space their movement into the mitochondria can be facilitated by mitochondrial 
anion carrier proteins. As the pH of the mitochondria is pH 8, this traps charged 
molecules and bioaccumulation can occur. 
Investigation into accumulation of xenobiotics within mitochondria using model 
compounds could help not only to predict mitochondrial liabilities but may also be 
useful as a pharmacological target. In chapter 4 it was demonstrated that increased 
concentrations of phenformin lead to increased lactate levels. The biguanides are 
known to accumulate into the liver via OCT1 (Sogame et al. 2011, Sogame et al. 
2009) and it has been demonstrated in isolated heart mitochondria that phenformin 
can accumulate against a concentration gradient into the mitochondria (Davidoff 
1971). This means that the biguanides could accumulate in liver mitochondria 
several thousand-fold the plasma Cmax. The biguanides as a class show increasing 
frequency of lactic acidosis as lipophilicity increases. The biguanides all have a 
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cationic charge at physiological pH, but the phenyl group on phenformin makes it 
much more lipophilic than its clinically safer counterpart metformin. Unfortunately, 
the metabolism of phenformin in metabolically competent cells, such as primary 
hepatocytes would not make it an ideal tool to investigate such accumulation. 
Conversely buformin, where the metabolically soft phenyl group is replaced by a 
butyl group, may be more suitable for such studies. 
5.5 CONCLUDING REMARKS 
 
Idiosyncratic reactions are not only a function of the chemistry of a drug but also the 
biology of the patient. Whilst much of this thesis has focussed on the potential 
toxicity caused through bioactivation to reactive metabolites, it has also 
demonstrated that mimicking CYP450 2D6 poor metabolisers, a function of the 
patient, can induce mitochondrial dysfunction. 
The investigations into the bioactivation and nefazodone and buspirone, ultimately 
concluded that in rat hepatocytes, at least, nefazodone is not responsible for 
cytotoxicity, but also highlighted the problems of predicting toxicity from 
bioactivation. The fact that buspirone demonstrated irreversible binding to the same 
extent as nefazodone in hepatocytes highlights this point. It still remains that in most 
cases the implications of bioactivation and irreversible binding of a compound 
cannot be predicted. Irreversible binding can only be a biomarker of bioactivation 
and not of toxicity. Whilst it is important to consider bioactivation potential and 
irreversible binding, toxicity studies incorporating these factors must be taken into 
account. Another important consideration is the predicted dose of the compound. If 
the dose is expected to be high then the daily body burden of a reactive metabolite is 
likely to be much higher and, therefore, more likely to overwhelm cellular defences.   
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Investigations into mitochondrial toxicity, using phenformin, demonstrated the 
patient component of idiosyncratic drug reactions. The inhibition of metabolism of 
phenformin demonstrated the increased likelihood of mitochondrial dysfunction that 
could be faced by CYP450 2D6 poor metabolisers. However, it was demonstrated 
that phenformin was not a suitable tool for the assessment of mitochondrial 
dysfunction in primary rat hepatocytes. 
The investigations presented in this thesis highlight the importance of understanding 
the role of drug bioactivation. Knowledge of drug bioactivation helps to further 
influence whether a drug should be progressed to clinical trials, however, a decision 
should be made in the context of other safety assessments. A more thorough 
understanding of the relationship between bioactivation potential and how this 
relates to clinical situations is required. A greater understanding of in vitro systems, 
and the tools we use to assess them, allows them to be used in an appropriate way in 
drug discovery and development. Ultimately understanding these in vitro tests and 
the model compounds used to assess them will help us to bridge the gap to man. 
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APPENDIX I 
 
AUC values for buspirone metabolites produced in rat liver microsomes. 
  
Name Peak AUC Percent total peak area 
(%)
Buspirone 1.87E+08 37.30077993
1-pyrimidinylpiperazine 2.03E+07 4.049229051
[2O] buspirone 1.71E+06 0.341092693
[2O] buspirone 2.55E+06 0.508646999
[2O] buspirone 3.54E+06 0.706121716
[2O] buspirone 6.43E+06 1.282588315
[O] buspirone 8.88E+07 17.71288373
Despyrimidinylpiperazine 1.57E+07 3.131669758
[O] buspirone 2.06E+07 4.109069874
[O] buspirone 9.46E+07 18.86980632
[O] buspirone 6.01E+07 11.98811162
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APPENDIX II 
 
AUC values for nefazodone metabolites produced in rat liver microsomes. 
 
  
Name Peak AUC Percent total peak area (%)
Nefazodone 8.17E+07 62.4569987
[2O] nefazodone 6.19E+06 4.732054124
[2O] nefazodone 3.51E+06 2.683281095
Phenoxyethyltriazolone n-propanol
2.51E+06 1.918813546
[O] nefazodone 2.09E+07 15.97737176
[O] nefazodone 9.89E+06 7.560584053
[O] nefazodone 1.15E+06 0.879137681
[=O] nefazodone 1.63e+006 1.246082104
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APPENDIX III 
AUC values for buspirone metabolites produced in rat hepatocytes 
Name Peak AUC Percent total peak area (%)
1-pyrimidinylpiperazine 7.60E+07 7.320150641
[2O] buspirone glucuronide 1.01E+07 0.972809493
[2O, OCH3] buspirone glucuronide 4.29E+05 0.041320324
[2O] buspirone glucuronide 9.52E+06 0.916945186
[2O] buspirone 1.27E+07 1.223235699
[2O] buspirone 1.38E+07 1.329185248
[2O] buspirone 8.73E+06 0.840854146
[2O, OCH3] buspirone glucuronide 3.27E+05 0.031495911
[2O] buspirone 4.62E+06 0.444988105
[2O] buspirone glucuronide 2.20E+07 2.118990975
[2O, OCH3] buspirone 1.41E+06 0.135808058
[2O] buspirone 2.50E+07 2.40794429
[O] buspirone 3.59E+07 3.457808
[2O, OCH3] buspirone 1.33E+06 0.128102636
[2O, OCH3] buspirone glucuronide 6.04E+05 0.058175934
[O] buspirone 7.52E+07 7.243096424
[2O] buspirone 3.36E+07 3.236277125
[O] buspirone glucuronide 1.05E+08 10.11336602
[O] buspirone 7.51E+07 7.233464647
[O, OCH3] buspirone glucuronide 1.28E+07 1.232867476
Despyrimidinyl buspirone 1.67E+06 0.160850679
[2O] buspirone 5.88E+07 5.66348497
[O, OCH3] buspirone 8.39E+06 0.808106104
[O] buspirone 1.35E+08 13.00289916
[O] buspirone 1.18E+08 11.36549705
Despyrimidinylpiperazine 2.82E+07 2.716161159
Buspirone 1.64E+08 15.79611454
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AUC values for nefazodone metabolites produced in rat hepatocytes 
 
 
 
 
Name Peak AUC Percent total peak area (%)
Nefazodone 1.60E+07 16.11717184
Deschlorophenyl nefazodone 1.03E+07 10.37542937
[2O] nefazodone glucuronide 6.17E+05 0.621518439
[2O] nefazodone glucuronide 2.06E+05 0.207508587
Chlorophenylpiperazine 3.88E+06 3.908414171
[O] nefazodone glucuronide 3.55E+06 3.575997502
[O] nefazodone glucuronide 3.50E+06 3.52563134
[2O] nefazodone 4.96E+06 4.99632327
[2O] nefazodone 4.04E+06 4.069585889
Nefazodone O-sulphonate 4.42E+05 0.445236872
Phenoxyethyltriazolone propanoate 3.33E+06 3.354386389
[O] nefazodone 2.10E+07 21.15378804
[O, =O] nefazodone 7.48E+05 0.753477783
[O] nefazodone 2.67E+07 26.89553051
[=O] nefazodone 3.14e+006 3.162994973
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AUC values for nefazodone metabolites produced in human hepatocytes 
Name Peak AUC Percent total peak area (%)
Nefazodone 1.61E+08 36.80757184
Hydroxychlorophenylpiperazine 4.88E+06 1.115658078
Deschloro [O] phenyl nefazodone 2.60E+06 0.594407993
[2O] nefazodone glucuronide 1.19E+06 0.272055966
Phenoxyethyltriazolone propanoate 6.67E+06 1.524885119
Chlorophenylpiperazine 2.63E+07 6.012665463
Deschlorophenylpiperazine nefazodone 6.69E+06 1.529457488
[O] nefazodone glucuronide 7.23E+06 1.652911456
[3O] nefazodone 1.23E+06 0.281200704
Phenoxyethyltriazolone n-propanol 9.84E+06 2.249605633
[2O] nefazodone 1.79E+07 4.09227041
Nefazodone O-sulphonate 6.68E+06 1.527171304
Desethylketo nefazodone 1.06E+07 2.423355662
[2O] nefazodone 1.15E+07 2.629112275
[O] nefazodone 3.61E+07 8.253126357
[O] nefazodone 2.54E+07 5.80690885
[O] nefazodone 4.85E+06 1.108799524
[O, = O] nefazodone 3.66E+06 0.836743559
[O] nefazodone 8.45E+07 19.31825976
[O, = O] nefazodone 6.51E+06 1.488306166
[O, =O] nefazodone 2.08E+06 0.475526394
[=O] nefazodone 1.25e+007 2.857730733
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